Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
White Paper and References Evidence of Associations and Treatment
Recommendations for Genes Analyzed by the
Mindful DNA™ Test.
April 2018
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Table of Contents
(Click on title name to hyperlink to location within document)
Purpose of Document
Categories of Evidence Strength and Definition
Evidence Summaries for Health Impact Claims
ABCA7: ATP-Binding Cassette A7 Protein
ACE: Angiotensin I Converting Enzyme
AKT1: Serine/Threonine Protein Kinase (Protein Kinase B)
ANK3: Ankyrin G
ApoE: Apolipoprotein
BDNF: Brain Derived Neurotrophic Factor
BNP: Brain Natriuretic Peptide
CACNA1C: Cav1.2 Voltage-Dependent L-Type Calcium Channel, α1C Subunit
CD33: Siglec-3, Compliment of Differentiation 33
CHRNA5/3: Cholinergic Receptor Nicotinic Alpha 5, Alpha 3 Subunits
CLOCK: Circadian Locomotor Output Cycles Kaput
COMT: Catechol-O-Methyltransferase
CRHR1: Corticotropin-Releasing Hormone Receptor
CRP: C Reactive Protein
FKBP5: FK506-Binding Protein 5
FTO: Alpha-Ketoglutarate-Dependent Dioxygenase
FUT2: Fucosyltransferase 2
HDAC9: Histone Deacetylase 9
HLA-DQ2.2/4/2.5/8: Major Histocompatibility Complex, Class II, DQ2 and 8
HLA-DQB1: Major Histocompatibility Complex, Class II, DQ Beta 1
IL6: Interleukin 6
LRP1: Low Density Lipoprotein Receptor-Related Protein 1
LRRK2: Leucine Rich Repeat Kinase 2
MC4R: Melanocortin 4 Receptor
MEIS1: Meis Homeobox 1
miR-181: miR-181 MicroRNA Precursor
MTHFR: 5,10 Methylenetetrahydrofolate Reductase
OXTR: Oxytocin Receptor
PCSK9: Proprotein Convertase, Subtilisin/Kexin-Type 9
PPARG: Peroxisome Proliferator-Activated Receptor Gamma
SMARCA4: Catalytic Subunit of the SWI/SNF Chromatin-Remodeling Complex
TREM2: Triggering Receptor Expressed on Monocytes 2
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Evidence Summaries for Key Recommendations
Agmatine
Ashwagandha
Berberine
Bright Light Therapy
Caffeine
Carotenoids
Coenzyme Q10 (CoQ10)
Curcumin
DASH Diet
Exercise and Caloric Restriction
Ferrous Sulfate
Hypertension Management to Reduce the Risk of Dementia
Lithium
L-Methylfolate (5-MTHF)
Magnesium
Mediterranean Diet
Melatonin
Memory and Learning is Modulated by High-Fat, High-Sugar Diet
Mindfulness & Meditation
N-Acetyl-Cysteine (NAC)
Neurofeedback: Quantitative Electroencephalography (qEEG)
Nicotine Replacement Therapy (NRT)
Omega-3 Poly-Unsaturated Fatty Acids (ω-3 PUFA)
Oxytocin
OXTR GG Genotype Greater Response to Social Support
Palmitoylethanolamide (PEA)
Petasite hybridus (butterbur)
Physical Activity Benefits Cognition and Mood
Polysomnography (PSG) & Actigraphy
Prebiotics
Probiotics
Quercetin and Epigallocatechin Gallate (EGCG)
Sodium Butyrate
Vitamin D
Domain Recommendations
COGNITION & MENTAL ACUITY
CARDIOMETABOLIC
GI & IMMUNE
STRESS & EMOTIONAL WELLBEING
INFLAMMATION
SLEEP
References
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Purpose and Intended Use of the Mindful DNA™ White Paper and References
The following is a summary of the key published literature relevant to a variety of genetic variations
analyzed by Mindful DNA. The purpose of this document is to summarize the available information.
Individual patients vary and this information is not intended to replace the clinician’s responsibilities in
clinical decision making.
Categories of Evidence Strength and Definition
The strength of evidence supporting the purported health impacts or mechanisms for each
polymorphism or haplotype (set of polymorphisms) may vary. The strength of the evidence is
categorized numerically 1-4, with 4 indicating stronger evidence for the association reported in Mindful
DNA.
Evidence level category descriptions:
Evidence category Minimum requirements for category
Evidence level 1 Preliminary evidence in at least 1 clinical study published in a peer-reviewed publication in good standing with the scientific community.
No compelling contradictory evidence.
Evidence level 2 Evidence in at least 2 clinical studies published in a peer-reviewed publication in good standing with the scientific community.
No compelling contradictory evidence.
Evidence level 3 Evidence in at least 2 clinical studies published in a peer-reviewed publication in good standing with the scientific community.
Well established biological plausibility.*
No compelling contradictory evidence. -OR-
At least 1 large GWASⱡ study or meta-analysis with significant
association in addition to at least one additional clinical study (if GWAS) supporting the association, but without a well-established biological plausibility.
Evidence level 4 At least 1 large GWAS study or meta-analysis with significant association.
At least 1 additional clinical trial (if GWAS).
Well established biological plausibility.*
No compelling contradictory evidence.
*Biological plausibility: The mechanism by which the genetic variant confers a health impact correlates
with the function of the expressed protein. Example: Angiotensin converting enzyme (ACE) is involved
in hemostasis and has a mechanism which acts to increase blood pressure. Thus, a genetic variant
which is associated with increased blood pressure and hypertension would have good biological
plausibility.
ⱡGWAS: Genome wide association study.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Evidence Summaries for Health Impact Claims
ATP-Binding Cassette A7 Protein (ABCA7)
ABCA7 encodes ATP-binding cassette A7 protein. In the brain, ABCA7 is highly expressed in hippocampal
CA1 neurons and microglial cells.4,7 ABCA7 is thought to play a role in Alzheimer’s disease (AD) through
three primary means. First, ABCA7 contributes to efflux of phospholipids and cholesterol, which is
hypothesized to be related to AD pathogenesis through amyloid β related pathways. Second, ABCA7
plays a major role in regulating phagocytosis of apoptotic cell debris. It is highly expressed in microglial
cells in which ABCA7 knockdown leads to ineffective engulfment of apoptotic debris.7 Finally, ABCA7
may be directly involved in amyloid β homeostasis. Meta-analyses have confirmed that the G allele of
the ABCA7 variant tested in Mindful DNA is associated with an approximate 17-20% increased likelihood
of developing AD with one risk allele (C/G).1,11 This variant demonstrates extremely robust associations
with AD, including associations with underlying neuropathology (e.g. neuritic plaque burden and
neurofibrillary tangles), as well as subsyndromal predictors of AD such as mild cognitive
impairment.2,3,5,6,8-10
Evidence Level 4
Angiotensin I Converting Enzyme (ACE)
The angiotensin I-converting enzyme, encoded by ACE, plays a role in the production of angiotensin II
(vasoconstrictor) and the catabolism of bradykinin and kallidin (vasodilators). The ACE enzyme is a key
component of the renin-angiotensin system, a major pathway and therapeutic target involved in the
pathogenesis of hypertension and cardiovascular disease.13 The much studied ACE (Ins/Del)
polymorphism confers increased ACE activity, and has been consistently linked to increased risk of
cardiovascular disease12-21 and metabolic syndrome.22,26 The ACE G2350A variant on the Mindful DNA
test is a well-validated surrogate marker for ACE (Ins/Del).23-25
Evidence Level 4
Serine/Threonine Protein Kinase (Protein Kinase B) (AKT1)
This gene encodes one of three isoforms of protein kinase B (PKB). PKB participates in the signaling of
multiple g-protein coupled receptors, including dopamine signaling, such that decreased AKT function
results in an increased DRD receptor stimulation.27 Cannabinoids interact with AKT1, 29,30 and AKT1
variants have been associated with development of psychotic symptoms in habitual marijuana users.31
The C/C genotype has been associated with a twofold increase in risk of psychotic symptom
development in cannabis users.28 While the AKT1 gene shows a relatively robust association with
psychotic symptoms in cannabis users, all studies focused on patients who reported cannabis use prior
to developing symptoms.
Evidence level 2 (CC genotype)
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Ankyrin G (ANK3) ANK3 belongs to a family of scaffolding proteins known as the ankyrins and plays a role in the
maintenance of sodium ion channels.41 A variation in this gene, the T allele, can potentially lead to
abnormal clustering of sodium channels and dysfunction in action potential firing.41 Genome wide
association studies (GWAS) have shown a correlation between this variation and disorders characterized
by mood instability and lability.32-35,39,40,42,43 Many studies indicate that this variant is associated with
changes in anatomical connections that may be related to cognitive and affective symptoms.35-38,44 More
specifically, this variation has been associated with anhedonia, altered novelty seeking, impaired
threat/stress signal processing, diminished cognition, working memory, and reduced integrity of white
matter tracts.34,36,38,45
Evidence level 4
Apolipoprotein (ApoE)
Apolipoprotein (ApoE) is a multifunctional protein with central roles in lipid metabolism, neurobiology,
and neurodegenerative diseases.48 It has three major isoforms (ε2, ε3, and ε4) with different effects
on lipid and neuronal homeostasis. The ε2 allele is the rarest form of APOE and carrying even one copy
appears to reduce the risk of developing Alzheimer's by up to 40% (resilience).46,52 ε3 is the most
common allele and doesn't seem to influence risk. The ε4 allele, present in approximately 10-15% of
people, increases the risk for Alzheimer's and lowers the age of onset. Having one copy of ε4 (ε3/ ε4)
can increase risk by 2 to 3 times while two copies (ε4/ ε4) can increase the risk by approximately 12 to
15 fold.47,49-51 However, like all variants on Mindful DNA, this is not deterministic. Up to 50% of
individuals with two ε4 alleles (high risk) have been observed to survive to age 80 without having
developed Alzheimer's disease.53,54
Evidence level 4
Brain Derived Neurotrophic Factor (BDNF)
BDNF regulates neuronal differentiation, migration, survival, and synaptic plasticity.67 Expressed in the prefrontal cortex (PFC) and hippocampus, BDNF has been implicated to play in role in etiology of several psychiatric disorders and the biology of learning and memory.61 It has been shown to influence synaptic plasticity by modulating hippocampal long-term potentiation.67 The Val66Met polymorphism is associated with reduced BDNF secretion, depression, and altered stress reactivity.55-59 Several studies indicate that physical activity may improve cognition and working memory in Met allele carriers and may be implemented as therapy, if clinically indicated.60,62-66 Evidence level 4
Brain Natriuretic Peptide (BNP)
BNP, encoded by NPPB, plays a role in regulation of circulatory volume, plasma renin-aldosterone concentrations, natriuresis, and maintenance of blood pressure. Elevated serum BNP levels stimulate natriuresis and diuresis as well as promoting peripheral vasodilation. Plasma BNP and NT-proBNP levels are used as biomarkers to aid in the diagnosis and prognosis of heart failure.75 Studies have repeatedly shown that the T381C polymorphism is associated with significantly increased expression of BNP.69-71,76
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Individuals with this polymorphism may benefit from this increased expression as it is associated with decreased blood pressure and decreased risk of hypertension,73,75 type 2 diabetes,68,72,74 and cardiovascular disease.70,77 Seidelmann et al. further showed that the C/C genotype resulted in lower rates of all-cause mortality and cardiovascular death in a 23-year follow up of 11,361 subjects.75
Evidence level 4
Cav1.2 Voltage-Dependent L-Type Calcium Channel, α1C Subunit (CACNA1C) CACNA1C is important in the regulation of calcium signaling; it encodes for an alpha-1 subunit of a voltage dependent calcium ion channel.78 ,79 Several GWAS have identified a variant in this gene, the A allele, to be associated with conditions related to mood instability and lability.80-88 Some studies noted disruptions in cognition among bipolar or schizophrenic patients as a function of rs1006737 status.93-95 Variations in this gene may lead to ion channel dysfunction, resulting in a prolongation of the period during which the pore remains open, leading to increased excitatory signaling.78,82 It has also been reported that this variant is associated with changes in amygdala volume,92 frontal‐hippocampal function,86,91 and this variant also has been hypothesized to be related to glutamate signaling.90 Evidence level 4
Siglec-3, Compliment of Differentiation 33 (CD33)
CD33 encodes a transmembrane glycoprotein that is expressed on the surface of microglia and is an
essential regulator of cell activity. Microglial cells are found in one of two states; monophagocytic or
neuroinflamatory. The monophagocytic state increases microglial clearance of amyloid and other
debris, whereas the neuroinflamatory state leads to oxidative stress and neuronal damage. CD33 can be
thought of as an “off switch” for the monophagocytic state.96 The A allele (resilient allele) of the CD33
variant on the Mindful DNA test confers reduced surface expression of CD33. Thus, ratio of
monophagocytic to neuroinflamatory microglial cells will be higher, with increased clearance of amyloid
and decreased risk of Alzheimer’s disease. The CA substitution confers an approximate 10% reduced
risk of developing late onset Alzheimer’s disease, as reported across multiple studies and recent met-
analyses.97-101
Evidence level 4
Cholinergic Receptor Nicotinic Alpha 5, Alpha 3 Subunits (CHRNA5/3)
Nicotine selectively binds to nicotinic acetylcholine receptors (nAChRs), partially encoded by CHRNA5
and CHRNA3, which opens an ion channel exerting its physiological effects. The receptors activate
neurons in the dopaminergic reward pathway and can facilitate nicotine dependence and addiction with
chronic exposure.102 Studies have shown that the functional variant at rs16969968 (D398N) is associated
with reduced receptor function.103 The A allele at rs16969968 has been shown to be associated with an
increased risk for nicotine dependence.104 Two other variants, rs578776 and rs588765, have been shown
to effect the mRNA expression levels of CHRNA5.105 The combined effect of the three variants may alter
the risk for nicotine dependence and smoking habits.106 Further, individuals at an increased risk that are
homozygous for the risk allele may have a higher chance of relapsing following smoking cessation.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
These individuals are more likely to reverse the risk of relapse using nicotine replacement therapy.107 An
opposing effect has been shown for the minor allele (A) at rs578776, where the variant is associated
with protection against nicotine dependence.108 Depending on the mRNA expression levels of
CHRNA5/3, which is influenced, in part, by the rs588765 allele, the overall risk for nicotine dependence
can be further increased.105 Saccone et al. confirmed the associations of nicotine dependence in a
meta-analysis of 34 studies involving current and former smokers (N=24,807).106
Evidence level 4
Circadian Locomotor Output Cycles Kaput (CLOCK)
CLOCK is one of the core genes involved in the “molecular clock,” governing circadian rhythm in the
body. CLOCK encodes the CLOCK transcription factor which is involved in a transcriptional/translational
feedback loop encompassing multiple genes that work to regulate circadian activity across a number of
biological functions including energy balance and metabolism. CLOCK variants have been associated
with obesity and eating behavior traits.109 The T3111C variant confers increased expression,110,111 as well
as an increased risk of obesity and metabolic syndrome.112-116 In some studies, the C allele was also
associated with diurnal preference and emotional eating behavior, both of which are postulated to play
a role in the observed increased risk of metabolic syndrome.117-120 Of note, the association between the
T3111C polymorphism and metabolic syndrome has not been observed in children or those with
comorbid cardiovascular disease, possibly due to confounding variables in these populations.121,122
Evidence level 3
Catechol-O-Methyltransferase (COMT)
COMT is an enzyme responsible for breakdown of dopamine in the frontal lobes of the brain,123 which is
critical for memory, attention, judgement, and other executive functions.127 The Val66Met variant
results in varying capacity of the enzyme to degrade dopamine.123,128 The Met allele results in reduced
enzymatic activity, while the Val allele results in increased activity.123,128,133 Patients who have normal
levels of dopamine degradation possess one increased and one decreased function allele (Val/Met).
Patients with the Val/Val genotype display elevated enzyme activity and increased dopamine
degradation; conversely, patients with the Met/Met genotype display reduced enzyme activity and
decreased dopamine degradation. Clinical studies have shown that the Val/Val genotype may have
negative influence regarding cognitive function, memory, retention, motivation, and judgement.123-126
Studies have shown that individuals with the Met/Met genotype may perform better on cognitive tasks,
including working memory and reward-learning,129-132 but may also be at increased risk of cognitive
perseveration, PTSD, OCD (in men), and addictive behavior.134-138
Evidence level 3
Corticotropin-Releasing Hormone Receptor (CRHR1)
CRHR1 encodes for the corticotropin-releasing hormone (CRH) receptor, which contributes to the HPA-
axis modulation of neuroendocrine and behavioral responses to stress. CRHR1 is essential for the
activation of signal transduction pathways that activate mesolimbic and hypothalamic-pituitary axis
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
(HPA) responses to many types of stress.141 Whereas CRHR1 helps establish the initial HPA axis response
to a stressful episode, the FKBP5 protein assists in terminating the stress response.140,142 The exact
mechanism by which the CRHR1 variant, analyzed by Mindful DNA, impacts stress response is not fully
understood. However, the G allele is associated with significantly increased cortisol in response to
stress,140,142 poor working memory,139,144 and increased rates of adult depression in the context of child-
hood trauma or maltreatment.143,145
Evidence level 3
C Reactive Protein (CRP)
CRP encodes for C-reactive protein, an acute phase reactant that is produced in response to
inflammation and tissue damage, and is a predictor of cardiovascular disease.147-149 To clarify whether
CRP is a bystander or active participant in atherogenesis, a 2008 study compared people with various
genetic CRP variants. Although CRP was associated with risk, those with a high CRP due to genetic
variation (including the variant analyzed by Mindful DNA) had no increased risk of cardiovascular disease
(CVD) compared to those with a normal or low CRP.150 This spurred two large meta-analyses which
confirmed that polymorphisms that cause an increase in serum CRP are not associated with increased
risk of CVD.146,151 Thus, although the T allele of the CRP variant is consistently associated with increased
serum CRP levels,146,152,153 this does not necessarily confer the risks normally associated with elevated
CRP. Interpretation of serum CRP levels should be made with the foreknowledge that T carriers may
have elevated baseline levels in excess of normal parameters that may not be associated with
cardiovascular or inflammatory pathology.
Evidence level 4
FK506-Binding Protein 5 (FKBP5)
Stress response is regulated by the hypothalamic-pituitary-adrenal (HPA) axis. Activation of the HPA triggers release of cortisol from the adrenal cortex that enters the bloodstream to act on target organs, thereby facilitating the “Fight or Flight” response.161,164,165 This process is tightly regulated by a negative feedback loop involving glucocorticoid receptors (GR). FKBP5 is a negative regulator of GR function, and changes in FKBP5 expression can have significant effects on HPA function.156,158-160 The T allele of the FKBP5 variant on the Mindful DNA test confers increased expression of the protein and dysregulated cortisol response to stress. This has been shown to potentiate the risk of depression, disassociation, and posttraumatic stress disorder following traumatic experiences such as injury or childhood trauma.154,155,157,162,163,166 Evidence level 4
Alpha-Ketoglutarate-Dependent Dioxygenase (FTO)
The FTO gene encodes an alpha-ketoglutarate-dependent dioxygenase, which is responsible for
methylation of amino acid and RNA nucleosides.167 It is unclear why variants in this gene result in
increased rates of metabolic syndrome, yet the TA variant analyzed by Mindful DNA maintains one of
the most robust and significant genetic links with metabolic syndrome yet discovered, with the largest
analysis showing a 0.39 kg/m2 change in BMI per copy of the A allele (p = 4.8x10-120)174 This finding has
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
been replicated across multiple populations. Additional evidence links the A allele with increased risk of
metabolic syndrome, including increased risk of obesity, type 2 diabetes, and cardiovascular disease,
possibly modulated by decreased satiety168-177
Evidence level 4
Fucosyltransferase 2 (FUT2) FUT2 encodes fucosyltransferase 2 that has been shown to affect the composition of intestinal microbiota due to the addition of an important fucose moiety to luminal surface receptors allowing bacterial attachment and growth.184,185 Multiple studies have linked the two polymorphisms analyzed by Mindful DNA (rs1047781 AT and rs601338 GA) with “non-secretor” status, meaning the variant confers altered fucosyltransferase activity. The non-secretor genotype confers altered vitamin B12 absorption and increased risk of Crohn’s disease,179-181 primary sclerosing cholangitis,178,183 celiac disease and inflammatory bowel disease.182 This is likely due to dysregulation of gut microbiota, as evidenced by several studies showing lower diversity of beneficial gut bacteria in non-secretors compared to secretors.183,186-188 Evidence level 3 (rs1047781) Evidence level 4 (rs601338)
Histone Deacetylase 9 (HDAC9)
HDAC9 is a member of a large family of genes that encodes proteins responsible for deacetylation of histones and, therefore, is involved in the epigenetic modification and transcriptional regulation of DNA. It inhibits myogenesis and is involved in cardiomyocyte and vascular smooth muscle cell development.192 The CT variant analyzed by Mindful DNA results in the thickening of the carotid intima-media, which is an independent predictor of stroke.191,194 Accordingly, the T allele is associated with an increased risk of stroke and coronary artery disease across multiple large studies and meta-analyses.189,190,193,195-197 Evidence level 4
Major Histocompatibility Complex, Class II, DQ2 and 8 (HLA-DQ2.2/4/2.5/8)
Celiac disease is an immune-mediated, gluten-induced disorder that presents primarily with
gastrointestinal symptoms, but may also lead to systemic complications.198 Celiac disease has a well-
established profile of diagnostic biomarkers and a genetic basis.199 The human leukocyte antigen (HLA)
haplotypes DQ2 and DQ8 (HLA-DQ2 and HLA-DQ8, respectively) are necessary for the development of
celiac disease, although not all individuals positive for DQ2 and DQ8 develop the disease.200 These
haplotypes refer to a set of HLA variants that encode heterodimers of major histocompatibility complex
(MHC) class II T cell antigens.201 Variants tend to occur in the antigen-binding site of these proteins. The
DQ2 and DQ8 haplotypes are key to binding gluten and mediating the immune response, allowing the
development of celiac disease.199 One of the earliest studies to suggest the association of specific HLA-
DQ heterodimers with celiac disease found that 90-95% of celiac patients carried the DQ2.5
haplotype.202 Mindful DNA utilizes “tagging SNPs”, that is, polymorphisms which predict the presence or
absence of the HLA phenotypes (DQ2.2, DQ2.5, DQ4 & DQ8) that confer an increased risk of celiac
disease. The validity of these tagging SNPs is supported across numerous studies.203-211
Evidence level 4
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Major Histocompatibility Complex, Class II, DQ beta 1 (HLA-DQB1)
Narcolepsy is a sleep disorder marked by excessive daytime sleepiness and cataplexy (muscle weakness
or paralysis triggered by strong emotion).212 There is evidence that the disorder has an autoimmune
etiology, as much of the strong genetic associations have been found in a region of the genome that
encompasses genes associated with the immune system, including those related to the human
leukocyte antigen (HLA) system.213 Many studies have shown that greater than 90% of individuals with
narcolepsy carry the HLA-DQB1*0602 allele. Conversely, it has been reported that 12-38% of the
general population unaffected by narcolepsy also carry this allele.214-216 Observed differences in the
levels of cerebrospinal fluid hypocretin (neuropeptides involved in the regulation of sleep and arousal)
between individuals positive and negative for HLA-DQB1*0602, along with evidence from several
immunological studies, suggest that the risk allele may cause disruption of the hypocretin pathway,
leading to an autoimmune reaction targeting hypocretin-producing neurons. In this way, the allele is
thought to influence the susceptibility to develop narcolepsy.217,218 The HLA-DQB1*0602 allele has also
been shown to be associated with increased susceptibility for developing multiple sclerosis, another
disease of the central nervous system, likely by a similar pathogenesis.219
Evidence level 4
Interleukin 6 (IL6)
Interleukin-6 (encoded by the IL6 gene) is secreted by T cells and macrophages to stimulate the acute
phase response (immune response), and is a primary determinant of hepatic production of C-reactive
protein, a marker of inflammation and tissue damage.220,221 The role of IL6 in the body is complex and
has been classified as both a pro- and anti-inflammatory cytokine, depending on cellular context. In
muscular tissue, it acts to acutely reduce inflammation222 but may also play a role in the deleterious,
pro-inflammatory cascade seen in chronic inflammation.223,224 The G174C polymorphism confers
reduced expression of IL-6. Healthy controls with the CC genotype showed significantly lower IL-6
plasma levels than G allele carriers.225 This variant has been implicated in a wide range of diseases with
an inflammatory etiology, including vascular dementia, chronic arthritis, inflammatory bowel conditions,
and fatigue, but with very few replications.226-229 However, a recent meta-analysis of 21 case-control
studies confirmed an association between G174C and periodontitis, an inflammatory condition affecting
the gingiva and teeth.230 C allele (resilient allele) carriers were found to have reduced odds of developing
periodontitis by 32% [OR 0.68 (0.56-0.83). P=0.049]. Of note, periodontitis has been proposed to be a
significant source of systemic inflammation and is an independent risk factor for cognitive decline and
dementia.231-233
Evidence level 2
Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)
Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in intracellular signaling,
particularly in vascular tissues, and regulates glucose metabolism in the brain and signaling of NMDA
(glutamate) receptors. LRP1 may play a role in vascular homeostasis.235,241,242 The TC variant analyzed
by Mindful DNA has been linked to a decreased risk of migraine in multiple GWAS and case-control
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
studies in Caucasian populations.235,237-240 In the larger studies, individuals carrying the C allele were 10-
27% less likely to have migraines.234,236, 238-240,243
Evidence level 4
Leucine Rich Repeat Kinase 2 (LRRK2)
The biological function of LRRK2 has not been clearly elucidated but investigators believe that it may be involved in regulating peroxidase activity, which is essential for preventing oxidative stress and neuronal degeneration. It is highly expressed in the putamen and substantia nigra; areas of the brain that are susceptible to degeneration in Parkinson’s disease.249 The G2019S variant causes an amino acid change from glycine to serine that may result in decreased peroxidase activity, oxidative cellular damage, and neurodegeneration.244 Clinical studies have consistently associated this variant with an approximate 10-fold increased risk of developing Parkinson’s disease.245,247,248 A recent GWAS identified this SNP as the leading genetic risk factor for the disease.246
Evidence level 3
Melanocortin 4 Receptor (MC4R)
NOTE: The MC4R variant on the Mindful DNA test is a different polymorphism than that analyzed by the Genecept Assay®. The information provided below applies ONLY to the MC4R variant listed in Mindful DNA report.
MC4R moderates the effects of leptin, a neurohormone involved with satiety, metabolism, and energy
balance. Variants of MC4R influence body mass index (BMI) and the risk of obesity.250 The TC variant
tested on the Mindful DNA test was identified as the strongest genetic association with increased BMI in
a 2008 meta-analysis consisting of over 16,000 subjects.251 This finding has been replicated consistently
across varying populations, with indications that the risk is mediated by increased food consumption,
likely resulting from decreased satiety signaling.252-255 Interestingly, more recent studies have further
shown that C allele carriers may be particularly likely to reap the benefits of adhering to a
Mediterranean diet to reduce the increased risk of diabetes conferred by this genotype.252,256 Similarly,
the Graff et. al. meta-analysis showed that the BMI-increasing effect (of the C allele) was 33% less in
active individuals than in inactive individuals.255 Thus, the genetic predisposition to obesity conferred by
this genotype, may be ameliorated with therapeutic lifestyle and dietary interventions.
Evidence level 4
Meis Homeobox 1 (MEIS1)
MEIS1 encodes a homeobox protein that is part of a regulatory network that is involved in spinal motor neuronal connectivity. The TG variant analyzed by Mindful DNA is strongly correlated with an increased risk of developing restless leg syndrome (RLS), a sensorimotor disorder characterized by unpleasant or uncomfortable sensations in the legs and an irresistible urge to move them, particular at night.257 The G allele has been associated with an approximately 30-70% increased likelihood of developing RLS.258-260,262-266 Both RLS and periodic limb movements of sleep are associated with increased rates of hypertension.261
Evidence level 4
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
miR-181 MicroRNA Precursor (miR-181)
MicroRNAs (miR) modulate gene expression by regulating messenger RNA (mRNA). miR-181 has been shown to be involved in the development of neurons by promoting spine formation and reducing dendrite branching and axon growth, possibly through an immunomodulatory mechanism.267,270 It is expressed in the nucleus accumbens (NAc) and hippocampus; the brain regions involved with pleasure, reward, and motivation.269,271 The A allele of mir-181 is a resilience allele, conferring decreased expression of miR-181a/b in the brain. This is associated with greater NAc reactivity to positive emotional stimuli, enhanced fear inhibition, and has been identified in two recent GWAS studies to be associated with positive emotion reactivity, spiritual well-being, and affect.268,269 Positive affect is associated with favorable psychological and physical outcomes in multiple longitudinal studies.272-274 Evidence level 3
5,10 Methylenetetrahydrofolate Reductase (MTHFR)
MTHFR is an enzyme responsible for catalyzing the conversion of folic acid to methylfolate. Methylfolate is the active form of folic acid, a vital precursor for the synthesis of norepinephrine, dopamine and serotonin.275 Two variations are tested within this gene. The T allele of the C677T variant and the C allele of the A1298C variant lead to reduced enzymatic activity of MTHFR, resulting in inefficient folic acid metabolism and production of methylfolate.276 Several studies have shown these variations are associated with depression, bipolar disorder, and schizophrenia.277 Studies in psychiatric patients analyzing the therapeutic efficacy of exogenous administration of L‐methylfolate have found superior outcomes when SSRI/SNRI treatment was supplemented with L‐methylfolate compared with SSRIs/SNRI treatment alone.278-281 A 2016 study with a methylfolate B‐vitamin complex showed depression remission rates of 42% as monotherapy when MTHFR genotype was taken into consideration.282 Preliminary data also suggest that biomarkers related to L‐methylfolate synthesis and/or metabolism may identify patients who would benefit from supplementation with L‐methylfolate.283
Evidence level 4
Oxytocin Receptor (OXTR)
Oxytocin is a neurohormone involved in sociality and empathy in adults, as well as emotional bonding
between parents and infants.287,289 A common variant in the gene that expresses oxytocin receptor
(OXTR) has been broadly linked to socially related personality traits and behaviors.286,291 Several large
studies have indicated that G allele homozygotes have greater measures of sociality than A allele
carriers.287,292-294 Accordingly, A allele carriers tend to experience less negative pressure from an adverse
social environment, but also tend to benefit less from positive social reinforcement and
support.284,285,288,290 Conversely, G allele homozygotes may be more influenced by their social
environment, which confers an increased risk of maladaptive behaviors in the context of social stress
such as childhood maltreatment or significant social pressure.285,292,294,295
Evidence level 3
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Proprotein Convertase, Subtilisin/Kexin-Type 9 (PCSK9)
PCSK9 expresses an enzyme that is strongly linked with lipoprotein homeostasis. Downregulation of
PCSK9 results in an increased expression of low-density lipoprotein receptors which, subsequently,
results in an increased metabolism (clearance) of cholesterol and LDL particles in the blood.301,302,307
Thus, it is not surprising that genetic variants which result in decreased expression of PCSK9 are
consistently associated with decreased cholesterol and LDL levels.296-299,303-305,308 Specifically, the C allele
of the TC missense variant analyzed by Mindful DNA not only results in decreased serum LDL, but has
also been linked to decreased risk of coronary artery disease (CAD) and myocardial infarction (MI) in
Caucasians.298,303,306,308 This association has not been observed in those of Asian or African descent.300,309
Evidence level 4
Peroxisome Proliferator-Activated Receptor Gamma (PPARG)
PPARG encodes a nuclear receptor that regulates gene expression and affects peroxisome activity,
playing a significant role in fatty acid oxidation and metabolism.310,311 The variant G allele at rs1801282
(Pro12Ala) has been shown to alter the ability of PPARG to bind target gene promoters. The reduced
binding function affects the ability of PPARG to regulate fatty acid metabolism, contributing to
dysregulated lipid levels.312 Multiple studies have demonstrated that C/G and G/G genotypes are
associated with decreased risk of type 2 and gestational diabetes compared to the C/C genotype.313-316
Conversely, a meta-analysis of 32,000 individuals found an association of C/C genotype with insulin
resistance and increased fasting glucose levels.317 A number of association studies and meta-analyses
have repeatedly demonstrated an association of C/G and G/G genotypes with increased body mass
index (BMI) and obesity.318-320 In contrast, individuals with the C/C genotype may be more likely to
benefit from physical training for weight loss.321-322 However, individuals with C/G and G/G genotypes
may have a health advantage compared to those with C/C genotype when adhering to a Mediterranean
diet; G allele carriers show reduced telomere shortening and overall greater telomere length following
dietary intervention with the Mediterranean diet.323
Evidence level 4
Catalytic Subunit of the SWI/SNF Chromatin-Remodeling Complex (SMARCA4)
The protein expressed by SMARCA4 is involved with epigenetic regulation, which can affect the rate of
gene transcription. SMARCA4 lies in close proximity to LDLR, the gene that expresses the low-density
lipoprotein receptor. Many studies of the polymorphism analyzed by Mindful DNA erroneously link this
SNP directly to LDLR, likely due to its close proximity as well as the strong influence of this
polymorphism on cholesterol and serum LDL.330,336,338,339 More importantly, the GT polymorphism has
been consistently linked across multiple studies with cardiovascular pathology, with the G (major) allele
conferring increased risk of early-onset myocardial infarction and coronary artery disease in Caucasian
and Asian subjects,324,327-329,331-334,337,339 but not in those of African descent.325,326 The link with
cardiovascular pathology may be due to the apparent effect of this polymorphism on serum LDL and
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
cholesterol. However, SMARCA4 has also been shown to affect vascular smooth muscle cell
proliferation, which may therefore also play a significant role in vascular pathology.335
Evidence level 4
Triggering Receptor Expressed on Monocytes 2 (TREM2)
TREM2 is a microglial surface receptor that triggers intracellular protein tyrosine phosphorylation and
plays an essential role in removing neural debris.343,345 Homozygous loss-of-function mutations in TREM2
have been associated with an autosomal recessive form of early-onset dementia.344 The TREM2 variant
analyzed by Mindful DNA confers an amino acid change from arginine to histidine at position 47 of the
protein (R47H). This reduces protein function and confers an approximately 3-fold risk of developing
Alzheimer’s disease in Caucasians, presumably due to decreased activation of the mophagocytic state of
microglia and increased neuroinflamatory activity.340-342
Evidence level 4
Key Recommendation Summaries
Agmatine
Preclinical data suggests that agmatine may help reduce the harmful effects of cortisol and stress.476
Prolonged treatment with high dose glucocorticoids (50 mug/kg/day) produced noticeable
neuronal structural changes in rats, such as the diminution and disarrangement of dendrites
and neurons in the hippocampus and prefrontal cortex. Simultaneous treatment with agmatine
(50 mg/kg/day) prevented these morphological changes. These results demonstrated that
agmatine has neuroprotective effects against structural alterations caused by glucocorticoids in
vivo.
Ashwagandha Ashwagandha may help to reduce elevated cortisol and reduce symptoms of anxiety.475
A total of 64 subjects with a history of chronic stress were randomized to receive 300 mg of ashwagandha root extract or placebo once daily for 60 days. The treatment group exhibited a significant reduction (P<0.0001) in scores on all the stress-assessment scales on Day 60, relative to the placebo group. The serum cortisol levels were substantially reduced (P=0.0006) in the Ashwagandha group, relative to the placebo group.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Berberine
Berberine, a natural PCSK9 inhibitor available as a supplement, at doses of 500-1000 mg/day, has been
shown to decrease non-HDL cholesterol levels in individuals with dyslipidemia.447-449
There is preliminary evidence that berberine may also improve insulin sensitivity in individuals with the
metabolic syndrome.450
Bright Light Therapy
Bright light therapy appears effective for seasonal affective disorder and non-seasonal major depressive
disorder, and may also be effective in certain disorders of the sleep-wake cycle.430-432
Caffeine
Caffeine consumption associated with decreased risk of developing Parkinson’s disease.371
A systematic review and meta-analysis of published epidemiological studies was conducted to
better estimate the effect of caffeine exposure on the incidence of Parkinson’s disease (PD). The
summary RR for the association between caffeine intake and PD was 0.75 [95% CI: 0.68-0.82],
with low to moderate heterogeneity (I2= 28.8%).
Caffeine consumption reduces the odds of developing PD in those with genetic predisposition conferred
by LRRK R1628P.372
A case control study involving 812 subjects consisting of individuals with PD and healthy controls
was conducted. Regular caffeine intake was associated with an over 5-fold decreased odds of
developing PD amongst those with LRRK2 R1628P risk variant compared to non-caffeine takers
with the same variant. For those with the wild type genotype, caffeine consumption was
associated with a 91% decreased likelihood of developing PD. Caffeine consumption was
associated with a decreased risk of developing PD, but with a particularly pronounced effect in
those with the LRRK R1628P risk variant.
Caffeine offers neuroprotection and prevents neurodegeneration and rescues motor function in
rotenone-induced rat models of Parkinson’s disease.373
Rats were divided into four groups: (1) control, (2) PD model induced by rotenone, (3) protected group
injected with caffeine and rotenone for 45 days (during the development of PD model), and (4) treated
group injected with caffeine for 45 days after induction of PD model. Caffeine protection and treatment
restored the depletion of midbrain and striatal dopamine induced by rotenone and prevented decline in
motor activities and muscular strength.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Carotenoids
Plasma lutein level is inversely associated with dementia risk.421
1,092 non-demented older participants, from the Three-City-Bordeaux cohort were followed for
up to 10 years (range: 1.8-10.8 years, median: 9.5 years). Dementia and AD were diagnosed by a
committee of neurologists. The concentration of plasma carotenoids (beta-carotene, alpha-
carotene, lycopene, lutein, zeaxanthin, and beta-cryptoxanthin) was determined at baseline.
During follow-up, 199 dementia cases, including 132 AD, occurred. After adjustment for
sociodemographic data, diet quality, and clinical variables, including baseline cognitive
performances, only higher lutein concentration, considered as a function of plasma lipids, was
consistently significantly associated with a decreased risk of all-cause dementia and AD (hazard
ratio (HR)=0.808, 95% CI 0.671-0.973, p=0.024 and HR= 0.759, 95% CI 0.600-0.960, p=0.021,
respectively).
Preclinical evidence suggests that that carotenoids may inhibit amyloid β aggregation by preventing the
formation of the fibril and through disruption of the Aβ aggregates.422
Histone deacetylase (HDAC) inhibitors, including carotenoids and other flavonoids such as beta
carotene, luteolin, and lycopene, have been associated with reduced risk of stroke.423
In a systematic review, recent studies indicated that high dietary intake of six main carotenoids (i.e.,
lycopene, beta-carotene, lutein, zeaxanthin, and astaxanthin) was associated with reduced risk of stroke
and cardiovascular disease.
Serum lycopene levels are inversely associated with risk of stroke.424
In a meta-analysis of lycopene and stroke risk, the pooled analysis of seven prospective studies, with
116,127 participants and 1,989 cases, demonstrated that lycopene decreased stroke risk by 19.3%
(RR=0.807, 95% CI=0.680-0.957) after adjusting for confounding factors. Circulating lycopene was
associated with a statistically significant decrease in stroke risk (RR=0.693, 95% CI=0.503-0.954).
Dietary lycopene intake is inversely associated with cardiovascular disease.425
Measures of lycopene intake were assessed for subjects from the Framingham Heart Study (N=5,209)
who were followed for over 10 years to characterize the relation between lycopene intake and
incidence of cardiovascular disease (CVD, n=314), coronary heart disease (CHD, n=171) and stroke
(n=99). Using an average of three intake measures with a 9-year follow-up, lycopene intake was
inversely associated with CVD incidence (HR 0.83, 95% CI 0.70, 0.98). Using an average of two intake
measures and 11 years of follow-up, lycopene intake was inversely associated with CHD incidence (HR
0·74, 95% CI 0.58, 0.94).
Astaxanthin, a dietary carotenoid found in shellfish and cold-water fish, has been shown to inhibit
HDAC9 in a preclinical study.426
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Coenzyme Q10 (CoQ10)
Supplementation with CoQ10, 100 mg twice per day, may modulate BNP levels and help support healthy
blood pressure.441
Supplementation with CoQ10, 100-150mg, daily has been shown to significantly reduce both the
severity and frequency of migraine attacks over a period of 3-4 months.442,443
Curcumin
Preliminary evidence suggests that curcumin may help prevent cognitive decline in older adults as well
as have immediate benefits on mood and memory, consistent with preclinical evidence suggesting a role
in neuritogenic processes and clearance of tau.397-399
A 12-month, randomized, placebo-controlled, double-blind study investigated the safety and
efficacy of curcumin supplementation to prevent cognitive decline in a population of 96
community-dwelling older adults. The decline in function of the placebo group at 6 months was
not observed in the curcumin treatment group.
In a randomized placebo-controlled trial of 60 healthy, older adults, working memory and mood
were significantly improved following curcumin supplementation, compared to placebo at 4
weeks. Significantly improved scores on sustained attention and working memory tasks were
also observed one hour after administration, compared to placebo.
DASH Diet
Dietary approaches to stop hypertension (DASH) is an effective diet plan to prevent and control
hypertension.433,434
Exercise and Caloric Restriction
Findings from the Food4Me European randomized controlled trial indicate greater weight loss for FTO
risk allele carriers with personalized weight reduction intervention.348
In a stratified randomized trial of personalized weight reduction interventions, including caloric
restriction and exercise, mean reductions in weight and waist circumference at month 6 were
greater for FTO risk allele carriers than for non-carriers [-2.28 kg (95% CI: -3.06, -1.48 kg) and -
1.99 kg (-2.19, -0.19 kg), respectively (P = 0.037); and -4.34 cm (-5.63, -3.08 cm) compared with -
1.99 cm (-4.04, -0.05 cm), respectively, (P = 0.048)].
Assessing gene-environment interaction effects of FTO, MC4R and lifestyle factors on obesity using an
extreme phenotype sampling design: results from the HUNT study.349
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
The effects of obesity-promoting minor-alleles of FTO and MCR4, and interactions with lifestyle
factors are age- and gender-related. A greater FTO effect on BMI was observed among men with
a regular intake of artificially sweetened beverages, compared to non-drinkers.
FTO genotype and weight loss in diet and lifestyle interventions: a systematic review and meta-
analysis.350
A meta-analysis of 10 studies (comprising 6951 participants) that reported the results of additive
genetic models showed that individuals with the FTO AA genotype had 0.44-kg (95% CI: 0.09
0.79 kg; P= 0.015) greater weight loss than those with the TT genotype following dietary
intervention. Differences in weight loss between the AA genotype and TT genotype remained
significant after adjustment for baseline BMI or body weight. These results suggest that
individuals carrying the homozygous FTO obesity-predisposing allele may lose more weight
through diet/lifestyle interventions than non-carriers.
PPARG genotype predicts weight loss through multidisciplinary therapy (e.g., dietary advice,
counseling, and exercise) to severely obese subjects.322
Genetic predisposition to weight gain was assessed in a sampling of 587 participants of
multidisciplinary obesity treatment program involving dietary advice, psychological counseling,
and increased physical activity. The C/G-G/G genotypes of PPARG were found to predict ≥5%
weight loss after 12 months.
Physical activity is associated with improved mood, cognition, and may slow telomere shortening.351-353
Commercial activity monitors, or “smart” wearable devices, may help to achieve the recommended
physical activity goals.354
Ferrous Sulfate
Individuals with restless leg syndrome (RLS) should be screened for ferritin levels. In those with ferritin
levels ≤75 μg/L, clinicians should consider prescribing ferrous sulfate with vitamin C.427
Hypertension Management to Reduce the Risk of Dementia
APOE ε4 is associated with hypertension and cardiovascular disease, both of which are independent risk factors for cognitive decline and dementia.451,452
Management of cardiovascular risk factors (diabetes, obesity, smoking, and hypertension) reduces the
risk of cognitive decline and may reduce the risk of dementia.453
The World Dementia Council, in collaboration with the Alzheimer’s Association, published a
consensus statement on modifiable risk factors influencing the risk of dementia. The authors
concluded that there was strong evidence that management of cardiovascular risk factors
(diabetes, obesity, smoking, and hypertension) reduces the risk of cognitive decline and
dementia.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Lithium
Microdose lithium treatment stabilizes cognitive impairment in patients with Alzheimer's disease.400
113 AD patients were randomized to receive 300 MICROgrams lithium (gluconate or carbonate) or placebo for 15 months. The treated group showed no decreased performance in the mini-mental state examination test, whereas the lower scores were observed for the control group during the treatment, with significant differences starting three months after the beginning of the treatment and increasing progressively. This data suggest the efficacy of microdose lithium treatment in preventing cognitive loss, reinforcing its therapeutic potential to treat AD using very low doses.
Lithium increases plasma BDNF.401
Ten subjects with bipolar I disorder were evaluated at baseline, during a manic episode, and after 28
days of lithium therapy initiated at 600mg/day and adjusted to attain therapeutic levels (0.6-
1.2mmol/L). Changes in plasma BDNF levels and Young Mania Rating Scale (YMRS) scores were
analyzed. A significant increase in plasma BDNF levels was observed after 28 days of therapy with
lithium monotherapy (510.9±127.1pg/mL) compared to pre-treatment (406.3±69.5pg/mL) (p=0.03).
Lithium has been shown to rescue microglial function and reverse the deleterious impact of TREM2 loss
of function in TREM2 knock-out mice.402
Lithium may have neuroprotective effects through an ANK3- mediated pathway to reduce excessive
glutamate dysfunction.403,404
L-Methylfolate (5-MTHF)
Elevated serum homocysteine, a marker of 5-MTHF deficiency, has been associated with atherosclerosis and depression.477-481 Supplementation with reduced B-vitamins including 5-MTHF significantly reduces depressive symptoms and serum homocysteine levels.482
330 adult patients with MDD (DSM-5) and positive for either MTHFR C677T or A1298C polymorphism were enrolled in a randomized, controlled, double-blind study to assess the safety and efficacy of a reduced B vitamin formulation in the treatment of MDD. Plasma homocysteine levels were measured at baseline and week 8. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate efficacy for MDD. Of the active treatment group, 131 (82.4%) showed a reduction in homocysteine (for a mean in this subgroup of 25%, P < .001). Placebo patients demonstrated a small elevation in homocysteine. Active-treatment patients demonstrated, on average, a 12-point reduction on the MADRS by week 8, and 42% achieved full remission (P < .001).
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Adjunctive 5-MTHF 15 mg/day with an SSRI or SNRI results in significantly increased response rate and reduction in depressive symptoms in patients with MDD.279
Magnesium
Low magnesium (Mg) levels have been associated with hypertension, coronary heart disease, and type 2
diabetes.435
In a meta-analysis of 11 prospective cohort studies, 5 reported results on CHD (38,808 individuals
[4437 cases] with an average 10.5-year follow-up), 3 on hypertension (14,876 participants [3149
cases] with a 6.7-year follow-up), and 4 on T2DM (31,284 participants [2680 cases] with an 8.8-year
follow-up). Comparing the highest to the lowest category of circulating Mg concentration, the
pooled RRs (95% confidence intervals [CIs]) were 0.86 (0.74, 0.996), 0.91 (0.80, 1.02), and 0.64 (0.50,
0.81) for incidence of CHD, hypertension, and T2DM, respectively. Every 0.1 mmol/L increment in
circulating Mg level was associated with a 4% (RR, 0.96; 95% CI: 0.94, 0.99) reduction in
hypertension incidence.
Oral Mg, at a dosage range of 400-800mg/day, has been shown to alleviate the frequency and intensity
of migraine across multiple clinical trials.436,437
500mg/day Mg supplementation increases the quality and duration of sleep in elderly subjects.438
46 elderly subjects were randomly allocated to receive 500 mg of Mg or placebo daily for 8 weeks.
Dietary Mg supplementation brought about statistically significant increases in sleep time (P = 0.002),
sleep efficiency (P = 0.03), concentration of serum renin (P < 0.001), and melatonin (P = 0.007), and also
resulted in significant decrease in sleep onset latency (P = 0.02) and serum cortisol concentration (P =
0.008).
Magnesium acts to inhibit calcium ion current at voltage gated calcium channels such as that expressed
by CACNA1C.439,440
Mediterranean Diet
Adherence to a Mediterranean diet reduces the risk of cognitive impairment and Alzheimer’s
disease.385,386
In a meta-analysis (Singh 2014), higher adherence to the Mediterranean diet (MeDi score) was
associated with reduced risk of mild cognitive impairment (MCI) and AD. The subjects in the
highest MeDi tertile had 33% less risk (adjusted HR = 0.67; 95% CI, 0.55-0.81; p < 0.0001) of
cognitive impairment (MCI or AD) as compared to the lowest MeDi score tertile. Among
cognitively normal individuals, higher adherence to the MeDi was associated with a reduced risk
of developing MCI (HR = 0.73; 95% CI, 0.56-0.96; p = 0.02) and AD (HR = 0.64; 95% CI, 0.46-0.89;
p = 0.007).
Olive oil polyphenols may increase the activity of the ATP binding cassette transporter and assist in
cholesterol efflux. Additionally, preclinical evidence suggests that olive oil polyphenols may inhibit Tau
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
aggregation into fibrillary tangles; a major contributor to Alzheimer's disease and related
tauopathies.387,388
Adherence to a Mediterranean diet reduces the risk of obesity, type 2 diabetes, gestational diabetes,
dyslipidemia, and cardiovascular disease across multiple populations.389-396
Associations of the FTO rs9939609 and the MC4R rs17782313 polymorphisms with type 2 diabetes are
modulated by diet, being higher when adherence to the Mediterranean diet pattern is low.256
A case-control study in 7,052 high cardiovascular risk subjects (3,430 type 2 diabetes cases and
3,622 non-diabetic subjects) revealed a gene-diet interaction supporting the Mediterranean diet
(MeDiet) as a risk reducing intervention. When adherence to the MeDiet was low, carriers of
the variant alleles of FTO and MC4R had higher type 2 diabetes risk than wild-type subjects.
However, when adherence to the MeDiet was high, these associations disappeared.
PPARG genotype interacts with a Mediterranean diet to prevent telomere shortening.323
521 subjects (55-80 years) participating in a dietary intervention trial were genotyped. Changes in
telomere length (TL) were assessed over 5 years of a nutritional intervention, which promoted
adherence to the Mediterranean diet (MeDiet). PPARG G allele carriers showed lower telomere
shortening after 5 years compared with the C/C genotype (P=0.031). This association was
modulated by MeDiet, as those G allele carriers who reported better conformity to the MeDiet
exhibited increased TL (P<0.001). Moreover, a reduction in carbohydrate intake (≤9.5 g/d) resulted
in increased TL among G allele carriers.
Melatonin
Prolonged release melatonin 2mg has been shown to have positive effects on cognitive functioning and
sleep maintenance in elderly patients with dementia.417,418
Melatonin has also been shown to inhibit amyloid aggregation in animal models of Alzheimer’s
disease.419
Preclinical evidence suggests that melatonin inhibits voltage-gated calcium channels like Cav1.2.420
Memory and Learning is Modulated by High-Fat, High-Sugar Diet
A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor (BDNF), neuronal
plasticity, and learning.367
Animals with increased brain-derived neurotrophic factor (BDNF) mRNA and protein in the hippocampus
have been shown to have accelerated learning within the spatial memory domain. Two months on a
high saturated fat and refined sugar diet were sufficient to reduce hippocampal levels of BDNF and
significantly decrease spatial learning performance.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Mindfulness & Meditation Meditation reduces cortisol levels, blood pressure, heart rate, triglycerides, and markers of inflammation in a range of populations.469-471
Meditation has also been shown to have a modest beneficial effect on cardiovascular risk.472
N-Acetyl-Cysteine (NAC)
NAC 2,400 mg per day may augment cognitive-behavioral therapy to improve post-traumatic stress
disorder (PTSD) symptoms. 379
Veterans with PTSD and substance abuse disorders (SUD) per DSM-IV criteria (N = 35) were
randomly assigned to receive a double-blind, 8-week course of NAC (2,400 mg/d) or placebo
plus cognitive-behavioral therapy for SUD. Primary outcome measures included PTSD symptoms
(Clinician-Administered PTSD Scale, PTSD Checklist-Military) and craving (Visual Analog Scale).
Participants treated with NAC compared to placebo evidenced significant improvements in PTSD
symptoms, cravings, and depression (β values < -0.33; P values < .05).
NAC 2.4-3.6 grams per day may reduce cigarette cravings and enhance the odds of successful smoking
cessation.382-384
Neurofeedback: Quantitative Electroencephalography (qEEG) Neurofeedback, utilizing qEEG, is an emerging technology that may be useful in alleviating symptoms of post-traumatic stress disorder.473,474
Nicotine Replacement Therapy (NRT)
The CHRNA5/A3 risk haplotype confers decreased odds of smoking abstinence without NRT, but not with NRT.466
2633 treatment-seeking smokers received interventions of: NRT, bupropion, varenicline, placebo (PLA), or combined NRT and bupropion, and five modes of group and individual behavioral therapy. CHRNA5/A3 risk alleles associated with smoking heaviness were significantly (P<0.05) associated with reduced abstinence in the placebo group. Conversely, subjects with the same risk variants had increased abstinence when cessation treatment included NRT.
The CHRNA5/A3 risk haplotype confers up to 2 to 3-fold increased odds of responding to smoking cessation pharmacotherapy.107,467
Cortisol regulation may be significantly impacted by smoking in FKBP5 TT homozygotes, which may make it harder to quit smoking.468
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Omega-3 Poly-Unsaturated Fatty Acids (ω-3 PUFA)
Correlation between ω-3 PUFA consumption and BDNF peripheral levels in adolescents. 355
Serum BDNF levels were assessed in a sample of 137 adolescents. ω-3 PUFA consumption was
estimated using a food frequency questionnaire for adolescents. There was a direct correlation
between ω-3 PUFA consumption and serum BDNF levels, which remained significant even after
accounting for potential confounders [rs=0.172, p=0.043].
Long-chain omega-3 fatty acids improve brain function and structure in older adults.356
65 healthy subjects (aged 50–75 years, 30 females) successfully completed 26 weeks of either
fish oil (2.2 g/day n3-PUFA) or placebo intake. Before and after the intervention period,
cognitive performance, structural neuroimaging, vascular markers, and blood parameters were
assayed. A significant increase in executive functions after ω-3 PUFA intervention compared
with placebo was observed (P=0.023). ω-3 PUFA exerted beneficial effects on white matter
microstructural integrity and gray matter volume in frontal, temporal, parietal, and limbic areas,
and on carotid intima media thickness and diastolic blood pressure. Improvements in executive
functions correlated positively with changes in omega-3-index and peripheral BDNF, and
negatively with changes in peripheral fasting insulin.
Increased serum-DHA decreases the risk of atherothrombotic stroke.357
Supplementation with high-dose (4 g/day) ω-3 fatty acid ethyl esters increases large and small artery
elasticity while decreasing blood pressure and plasma triglycerides in obese adults.358
DHA supplementation prior to the onset of Alzheimer’s disease may reduce the risk associated with
APOE ε4.359
Although randomized clinical trials of ω-3 in symptomatic AD have had negative findings, several
observational and clinical trials of ω-3 in the predementia stage of AD suggest that ω-3
supplementation may slow early memory decline in APOE4 carriers. Several mechanisms by
which the APOE4 allele could alter the delivery of DHA to the brain may be amenable to DHA
supplementation in predementia stages of AD. The association of cognitive benefit with DHA
supplementation in predementia, but not AD dementia, suggests that early ω-3
supplementation may reduce the risk for or delay the onset of AD symptoms in APOE4 carriers.
DHA supplementation reduces markers of inflammation and dyslipidemia in obese men and
women.360,361
In a double-blind, randomized, crossover, controlled study, 154 subjects with abdominal obesity
and low-grade systemic inflammation consumed 2.7 g/day DHA, 2.7 g/day EPA, or corn oil
(control) for 10 weeks. DHA compared with EPA led to more pronounced reductions in
triglycerides (-13.3% ± 2.3% compared with -11.9% ± 2.2%, respectively; P = 0.005) and
cholesterol:HDL-cholesterol ratio (-2.5% ± 1.3% compared with 0.3% ± 1.1%, respectively;
P=0.006). Additionally, supplementation with DHA compared with supplementation with EPA
led to a greater reduction in several inflammatory markers including CRP and IL6.
1-2 grams of omega-3 fatty acids per day can help decrease symptoms of depression.89,362,363
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
The most recent meta-analysis conducted by Mocking et al supported an overall beneficial
effect of omega-3 PUFAs on depressive symptoms in major depressive disorder. Meta-
regression showed that higher EPA dose (β=0.00037 (0.00009-0.00065), P=0.009) and higher
percentage antidepressant users (β=0.0058 (0.00017-0.01144), P=0.044) were significantly
associated with better outcome for PUFA supplementation. This is consistent with an earlier
meta-analysis (Sarris 2012 and Kraguljac 2009) which indicated that omega-3 PUFA
supplementation of 2200 g/day with a high EPA content was effective for depressive symptoms
and bipolar depression, but not mania.
Omega-3 fatty acids suppress transmembrane voltage-gated Na+ and Ca+ currents, supporting utility of
supplementation for CACNA1C and ANK3 polymorphisms which confer dysregulation of excitatory
signaling.364-366
Oxytocin (Exogenous)
Adjunctive administration of oxytocin (OT) has been shown to decrease symptoms of depression when added to prescription escitalopram over 4 weeks.483 Administration of exogenous OT has been shown to increase self-reported spirituality when combined with meditation.484 Midlife male participants (N = 83) were randomly assigned to receive intranasal OT or placebo
prior to 20-minute guided meditation. Results showed that intranasal OT increased self-reported spirituality on two separate measures and this effect remained significant a week later. It also boosted participants' experience of specific positive emotions during meditation, at both explicit and implicit levels
Intranasal OT increases neural responses to social reward in post-traumatic stress disorder.485 Male and female police officers with (n = 35) and without PTSD (n = 37) were included in a double-blind, randomized, placebo-controlled cross-over fMRI study. After intranasal OT (40 IU) and placebo administration, a social incentive delay task was conducted to investigate neural responses during social reward and punishment anticipation and feedback. Under placebo, PTSD patients showed reduced left anterior insula (AI) responses to social rewards (i.e. happy faces) compared with controls. OT administration increased left AI responses during social reward in PTSD patients, such that PTSD patients no longer differed from controls under placebo.
OXTR GG Genotype Greater Response to Social Support
OXTR genotype modulates response to social support, such that those with the G/G genotype benefit more from positive social support, but may be more vulnerable to negative social interactions.486,487
Individuals with the GG genotype evidence higher prosocial temperament and reduced cortisol responses to stress. While GG carriers may be buffered against stressors in the presence of social
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
support, they may be more susceptible to such stress in its absence, for example in the face of prior childhood maltreatment. Individuals with this genotype may benefit from increased social support to mitigate the effects of adverse life events.
Palmitoylethanolamide (PEA) PEA, a dietary compound found in egg yolk, was shown to decrease inflammatory markers and signs of
ulcerative colitis in a preclinical model inflammatory bowel disease.465
Petasite hybridus (Butterbur)
Supplementation with 50 to 75 mg of butterbur has been shown to be an effective prophylactic
treatment of migraine.444-446
Physical Activity Benefits Cognition and Mood
Physical exercise improves peripheral BDNF levels and cognitive functions in mild cognitive impairment
in elderly individuals with different BDNF Val66Met genotypes.346
The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy
adults: a meta-analysis.347
This meta-analysis sought to determine the effect of a single exercise session on concentrations
of BDNF in peripheral blood in order to evaluate the potential role of BDNF in mediating the
beneficial effects of exercise on brain health. In 55 studies that met inclusion criteria,
concentrations of peripheral blood BDNF were higher after exercise (Mean change= 0.59, 95%
CI: 0.46-0.72, P < 0.001). In meta-regression analysis, greater duration of exercise was
associated with greater increases in BDNF.
Polysomnography (PSG) & Actigraphy
In individuals with an ambiguous history of RLS, PSG to assess for periodic leg movements may be useful
to help confirm an RLS diagnosis.428
Actigraphy is indicated as a method to characterize circadian rhythm patterns or sleep disturbances in
individuals with chronic insomnia, including insomnia associated with depression.429,430
Prebiotics
There is strong evidence that a diet including low fermentable oligosaccharides may benefit individuals with irritable and inflammatory bowel disease.459-464
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Probiotics
There is substantial support for the role of probiotics in the maintenance of immunologic equilibrium in the GI tract.454-456
Probiotics such as Lactobacillus may be beneficial in the treatment of initial to moderate periodontitis.457,458
Quercetin and Epigallocatechin Gallate (EGCG)
Quercetin and EGCG significantly decrease catechol-O-methyltransferase activity and expression.374,375
Green tea consumption is associated with lower prevalence of cognitive impairment.376
A cross-sectional data from a community-based cohort consisting of 1003 elderly Japanese
showed that volume of green tea consumption was inversely associated with prevalence of
cognitive impairment. After adjustment for potential confounders, the odds ratios (OR)s for
cognitive impairment associated with different frequencies of green tea consumption were 1.00
(reference) for ≤ 3 cups/week, 0.62 (95% CI: 0.33, 1.19) for 1 cup/day, and 0.46 (95% CI: 0.30,
0.72) for ≥ 2 cups/day (P value for trend =0.0006).
Quercetin is associated with preserved cognitive function over time in a large, multi-ethnic cohort of
middle-aged adults.377
Dietary intake of flavonols was assessed from a large biracial study of 10,041 subjects, ages 45-
64, by analysis of a food frequency questionnaire administered at visit 1 of triennial visits.
Cognitive function was assessed at visits 2 and 4 with the following three cognitive performance
tests: the delayed word recall test, the revised Wechsler Adult Intelligence Scale digit symbol
subtest, and the word fluency test of the Multilingual Aphasia Examination. The change in each
score and a combined standardized change score over 6 years was calculated. Generalized
linear models controlled for age, ethnicity, gender, education level, energy intake, current
smoking, physical activity, body mass index, diabetes, and vitamin C intake. Total flavonols
across quintiles of intake were positively associated with preserved combined cognitive function
(P<.001). This pattern with preserved combined cognitive function was consistent for the three
major individual flavonols in the diet, myricetin, kaempferol, and quercetin (each P<.001). The
positive association with total flavonols was strongest for the digit symbol subtest (P<.001). In
this cohort, flavonol intake was correlated with protected cognitive function over time.
EGCG confers immediate benefits on cognition and mood.378
In a small, double blind, placebo controlled cross-over study (n=31) to assess safety and efficacy
of a purified formulation of EGCG, participants completed baseline assessments of cognitive and
cardiovascular functioning, mood, and a resting state electroencephalogram (EEG) before and
then 120 min following administration of 300 mg EGCG or matched placebo. EGCG
administration was associated with a significant overall increase in alpha, beta and theta
activity, also reflected in overall EEG activity, more dominant in midline frontal and central
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
regions, specifically in the frontal gyrus and medial frontal gyrus. In comparison to placebo, the
EGCG treatment also increased self-rated calmness and reduced self-rated stress.
Green and black teas are a rich source of polyphenols including epigallocatechin-3-gallate (EGCG) and
theaflavins, which may have neuroprotective as well as anti-oxidant properties.380
Tea drinking is associated with decreased risk of developing Parkinson's disease.381
A meta-analysis of publications evaluating the risk of Parkinson’s disease associated with tea
drinking included 8 studies comprising 1418 cases and 4250 controls. The pooled odds ratio
(95% CI) was 0.85 (0.74–0.98), which suggests a protective effect of tea drinking for the risk of
PD. However, sub-group analysis did not reveal a dose-response relationship between the
volume of tea consumed and effect on risk of developing PD.
Sodium Butyrate
Antidepressant-like effects of sodium butyrate (NaB) may be due to upregulation of BDNF, as
demonstrated in animal models wherein NaB ameliorated the behavioral and physiological markers of
chronic stress.368,369
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota
and gastrointestinal barrier.370
NaB corrected high-fat diet (HFD)-induced gut microbiota imbalance in mice, considerably
elevating the abundance of the beneficial bacteria Christensenellaceae, Blautia and
Lactobacillus. Further, NaB restored HFD-induced intestinal mucosa damage and decreased the
levels of gut endotoxin in serum and liver compared with high fat group. Several markers of
inflammation were reduced in liver or epididymal fat in NaB treated mice.
Vitamin D
Vitamin D may play a key role in blood pressure regulation.405
Improved serum 25(OH) vitamin D concentrations in hypertensive individuals who were vitamin
D insufficient were associated with improved control of systolic and diastolic BP. At baseline,
592 participants (7.3%) were hypertensive; of those, 71% were no longer hypertensive at follow-
up (12 ± 3 months later). There was a significant negative association between BP and serum
25(OH) vitamin D level (systolic BP: coefficient = -0.07, p < 0.001; diastolic BP: coefficient = -0.1,
p < 0.001). Reduced mean systolic (-18 vs. -14 mmHg) and diastolic (-12 vs. -12 mmHg) BP, pulse
pressure (-5 vs. -1 mmHg) and mean arterial pressure (-14 vs. -13 mmHg) were not significantly
different between hypertensive participants who did and did not take BP-lowering medication.
Serum 25(OH) vitamin D level is inversely associated with the risk of developing dementia, including
AD.406-408
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
In a meta-analysis of 5 cross-sectional and 2 longitudinal studies comprising 7,688 participants
showed an increased risk of cognitive impairment in those with low vitamin D compared with
normal vitamin D (OR 2.39, 95% CI 1.91-3.00; p < 0.0001).
Lower vitamin D levels have been shown to effect TREM2 expression and are correlated with cognitive
decline and Alzheimer's disease.409,410
Low vitamin D levels have been implicated in depression and anxiety across multiple populations.411-413
Vitamin D strengthens FKBP5-mediated inhibition of glucocorticoid receptor transport.414
In in vitro studies, vitamin D was shown to increase FK506-binding protein 5 (FKBP5) impact on the
phosphorylation status of glucocorticoid receptor in human peripheral blood mononuclear cells,
suggesting that 25(OH) vitamin D may act to attenuate the stress response.
Serum levels of 25(OH) vitamin D are inversely associated with serum CRP, as well as diastolic
dysfunction and severity of coronary artery disease.415,416
Domain Recommendations: COGNITION & MENTAL ACUITY
Diabetes, obesity, smoking status, and hypertension are all significant, modifiable risk factors for cognitive decline. Additionally, treatment of sleep dysregulation has been shown to significantly reduce the risk of dementia. Physical activity and cognitive training interventions may have more immediate benefits. Significant increases to working memory as well as delayed and immediate recall have been observed in individuals following these interventions.346,347,488-492
Domain Recommendations: CARDIOMETABOLIC Diets which increase fiber & unsaturated fats, while limiting intake of refined sugars, salt, and saturated and trans-fats, are widely supported as a powerful method to improve cardiovascular health. Physical activity, whether it’s a daily walk in the park, yoga, or vigorous athletic training, has been shown to be a great benefit to improve health over multiple domains.493-496
Domain Recommendations: GI & IMMUNE The gut microbiome is critical to immune system function. Overuse of antibiotics can contribute to disturbances in the gut microbiome, which can increase the risk of infections as well as inflammatory bowel symptoms. Probiotics and prebiotics increase favorable microbiome composition that contributes to overall health and immune system function. Management of irritable bowel symptoms includes eating smaller, more frequent meals and avoiding trigger foods.497-500
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
Domain Recommendations: STRESS & EMOTIONAL WELLBEING Chronic stress can have widespread negative impacts across all other domains. Mindfulness, meditation, yoga, progressive muscle relaxation, tai chi, and other forms of physical exercise are well studied methods to reduce stress. One of the most promising candidates to monitor stress is heart rate variability (HRV). Decreased heart rate variability has been associated with stress-related disorders and increased morbidity and mortality. Interventions that increase HRV, such as mindfulness, may promote stress reduction.501-507
Domain Recommendations: INFLAMMATION Chronic inflammation has been implicated in cancer, cardiovascular disease, metabolic disorder, and cognitive decline. Decreased consumption of saturated fats and increased consumption of omega-3 fatty acids have been shown to reduce inflammation and improve markers of health across multiple domains. The Mediterranean Diet has been demonstrated to reduce the risk of cardiovascular events, stroke, and diabetes. Low-glycemic diets may reduce inflammation, oxidative stress, and markers of insulin resistance.502-515
Domain Recommendations: SLEEP
Sleep dysregulation is a major risk factor for multiple physical and neuropsychiatric disorders, including obesity, cardiovascular disease, dementia, and mood and affective disorders. There are several modifiable factors that can improve sleep. Avoiding alcohol and caffeinated drinks late in the evening can increase sleep duration and quality. Low glycemic load meals with a focus on vegetables and protein and increased physical activity can help maintain alertness and improve sleep quality at night.516-521
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
References
1. Bao J, Xiao-jie W, Zong-fu M. Associations between genetic variants in 19p13 and 19q13 regions and
susceptibility to Alzheimer disease: a meta-analysis. Med Sci Monit 2016;22:234-243.
2. Carrasquillo MM, Crook JE, Pedraza O, Thomas CS, Pankratz VS, Allen M, et al. Late-onset Alzheimer’s risk
variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease. Neurobiol Aging 2015;
36(1):60-7.
3. Engelman CD, Koscik RL, Jonaitis EM, Okonkwo OC, HermannBP, LaRue A, et al. Interaction between two
cholesterol metabolism gene influences memory: findings form the Wisconsin Registry for Alzheimer’s
Prevention. J Alzheimers Dis 2013;36(4):749-57.
4. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry
2015;77(1):43-51.
5. Karch CM, Jeng AT, Nowotny P, Cruchaga C, Goate AM. Expression of novel Alzheimer’s disease risk genes in
control and Alzheimer’s disease brains. PLoS One 2012;7(11):e50976.
6. Vasquez JB, Fardo DW, Estus S. ABCA7 expression is associated with Alzheimer’s disease polymorphism and
disease status. Neurosci Lett 2013;556-58-62. Doi: 1016
7. Zhao QF, Yu JT, Tan MS, Tan L. ABCA7 in Alzheimer’s disease. Mol Neurobiol 2015;51(3):1008-16.
8. Schott JM, Crutch SJ, Carrasquillo MM, et al. Genetic risk factors for the posterior cortical atrophy variant of
Alzheimer's disease. Alzheimers Dement. 2016;12(8):862-71.
9. Shulman JM, Chen K, Keenan BT, et al. Genetic susceptibility for Alzheimer disease neuritic plaque pathology.
JAMA Neurol. 2013;70(9):1150-7.
10. Andrews SJ, Das D, Anstey KJ, Easteal S. Late Onset Alzheimer's Disease Risk Variants in Cognitive Decline: The
PATH Through Life Study. J Alzheimers Dis. 2017;57(2):423-436.
11. Liu G, Li F, Zhang S, et al. Analyzing large-scale samples confirms the association between the ABCA7 rs3764650
polymorphism and Alzheimer's disease susceptibility. Mol Neurobiol. 2014;50(3):757-64.
12. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, et al. Plasma level and gene polymorphism of
angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994;90(2):669-76.
13. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for
angiotensin-converting enzyme in a potent risk factor for myocardial infarction. Nature 1992;359(6396):641-4.
14. Danser AH, Schalekamp MA, Bax WA, van denBrink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting
enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92(6):1387-8.
15. Mehri S, Mahjoub S, Hammami S, Zaroui A, Frih A, Betbout F, et al. Renin-angiotensin system polymorphisms in
relation to hypertension status and obesity in a Tunisian population. Molecular Biology Reports 2011;39(4):4059-
65.
16. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, Miyakawa T, et al. Deletion polymorphism of the angiotensin I-
converting enzyme gene is associated with serum ACE concentration and increased risk of CAD in the Japanese.
Circulation 1994;90(5):2199-202.
17. O’Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and
genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but
not women in the Framingham Heart Study. Circulation 1998;97(18):1766-72.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
18. Zintzaras E, Raman G, Kitsios G, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphic
variant as a marker of coronary artery disease: a meta analysis. Arch Intern Med 2008;168(10):1077-89.
19. Saeed mahmood M, Saboohi K, Osman ali S, Bokhari AM, Frossard PM. Association of the angiotensin-
converting enzyme (ACE) gene G2350A dimorphism with essential hypertension. J Hum Hypertens.
2003;17(10):719-23.
20. Agerholm-larsen B, Nordestgaard BG, Tybjaerg-hansen A. ACE gene polymorphism in cardiovascular disease:
meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol. 2000;20(2):484-92.
21. Samani NJ, Thompson JR, O'toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion
allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94(4):708-12.
22. Mao S, Huang S. A meta-analysis of the association between angiotensin-converting enzyme insertion/ deletion
gene polymorphism and the risk of overweight/obesity. J Renin Angiotensin Aldosterone Syst. 2015;16(3):687-
94.
23. Abdollahi MR, Huang S, Rodriguez S, et al. Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in
the British Women's Heart and Health Study (BWHHS). Dis Markers. 2008;24(1):11-7.
24. Chung CM, Wang RY, Chen JW, et al. A genome-wide association study identifies new loci for ACE activity:
potential implications for response to ACE inhibitor. Pharmacogenomics J. 2010;10(6):537-44.
25. Yu B, Zheng Y, Alexander D, Morrison AC, Coresh J, Boerwinkle E. Genetic determinants influencing human serum
metabolome among African Americans. PLoS Genet. 2014;10(3):e1004212.
26. Xi B, Ruiter R, Chen J, Pan H, Wang Y, Mi J. The ACE insertion/deletion polymorphism and its association with
metabolic syndrome. Metab Clin Exp. 2012;61(6):891-7.
27. Arquello PA, Gogos JA. A signaling pathway AKTing up in schizophrenia. J Clin Invest 2008;118(6):2018-21.
28. Di Forti M, Iyeqbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. Confirmation that the AKT1 (rs2494732)
genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012;72(10):811-6.
29. Morgan CJ, Freeman TP, Powell J, Curran HV. AKT1 genotype moderates the acute psychotomimetic effects of
naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry 2016;16;6:e738. Doi/tp.2015.219.
30. Ozaita A, Puighermanal E, Maldonado R. Regulations of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J
Neurochem 2007;102(4):1105-14.
31. van Winkel R, van Beveren NJ, Simons C, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. AKT1
moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmaocology
2011;36(12):2529-37.
32. Schulze TG, et al. Two variants in Ankryin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Mol.
Psychiatry 14, 487-491 (2009)
33. Yuan A, et al. ANK3 as a risk gene for schizophrenia: new data in Han Chinese and meta-anlysis. Am. J. Med.
Genet. B. Neuropsychiatr. Genet. 159B, 997-1005 (2012).
34. Leussis MP, et al. Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology.
Biology of mood & anxiety disorders 2, 18 (2012)
35. Linke J, et al. Genome-wide supported risk variant for bipolar disorder alters anatomical connectivity in the
human brain. Neuroimage 59, 3288-3296 (2012).
36. Delvecchio G, et al. The effect of ANK3 bipolar-risk polymorphisms on the working memory circuitry differs
between loci and according to risk-status for bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168B,
188-196 (2015).
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
37. Zhang C, et al. Genetic modulation of working memory deficits by ankyrin 3 gene in schizophrenia. Prog
Neuropsychopharmacol. Biol. Psychiatry 50, 110-115 (2014).
38. Ruberto G, Vassos E, Lewis CM, Tatarelli R, Girardi P, Collier D, et a. The congnitive impact of the ANK3 risk
variant for bipolar disorder: initial evidence of selectivity to signal detection during sustained attention. PLoS one
2011;6(1):e16671.
39. Nie F, et al. Genetic analysis of SNPs in CACNA1C and ANK3 gene with schizophrena: A comprehenzie meta-
anlysis. Am. J. Med. Genet. B Neuropsychiatri. Genet. 168, 637-648 (2015).
40. Szczepankiewicz A. Evidence for single nucleotide polymorphisms and their association with bipolar disorder.
Neuropsychiatr Dis Treat. 9, 1573-1582 (2013).
41. Shirahata et al. Ankyrin-G regulates inactivation gating of the neuronal sodium channel, Nav16. J. Neurophysiol.
96, 1347-1357 (2006).
42. Nurnberger JI et al. Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry 71, 657-664
(2014).
43. Ferreira MA, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in
bipolar disorder. Nat. Genet. 40, 1056-1058 (2008).
44. Gurung R, et al. What is the impact of genome-wide supported risk variants for schizophrenia and bipolar
disorder on brain structure and function? A systematic review. Psychol. Med. 45, 2461-2480 (2015).
45. Hatzimanolis A, Smyrnis N, Avramopoulos D, Stefanis CN, Evdolimidis I, Stefanis NC. Bipolar disorder ANK3 risk
variant effect on sustained attention is replicated in a large healthy population. Psychiatr Genet 2012;22(4):210-
3.
46. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.
Nat Rev Neurol. 2013;9(2):106-18.
47. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of
apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science
1993;261(5123):921-3.
48. Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and
Alzheimer’s diseases. Neurobiol Dis 2014;72 PtA:3-12.
49. Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, et al. Transethnic genome-wide scan identifies
novel Alzheimer’s disease loci. Alzheimers Dement 2017;13(7):727-38.
50. Lee E, Giovanello KS, S Aykin AJ, Xie F, Kong D, Wang Y, et al. Single-nucleotide polymorphisms are associated
with cognitive decline at Alzheimer’s disease conversion within mild cognitive impairment patients. Alzheimers
Dement (Amst) 2017;8:86-95.
51. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. Association of
apoliprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology
1993;43(8):1467-72.
52. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset
Alzheimer disease. Nat Genet. 1994;7(2):180-4.
53. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between
apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis
Consortium. JAMA. 1997;278(16):1349-56.
54. Bird TD. Genetic aspects of Alzheimer disease. Genet Med. 2008;10(4):231-9.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
55. Notaras M, et al. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility:
progress and controversy. Mol. Psychiatry 20, 916-930 (2015)
56. Hosang GM, et al. interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic
review and meta-analysis. BMC Med. 12, 7 (2014).
57. Lau JY, et al. BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to
emotional faces in anxious and depressed adolescents. Neuroimage 53, 952-961 (2010).
58. LeMoult J, et al. Predicting change in symptoms of depression during the transition to university: the roles of BDNF and working memory capacity. Cogn. Effect. Behav. Neurosci. 15, 95-103 (2015).
59. Yu H, et al. Variant brain-derived neutrotrophic factor Val66Met polymorphism alters vulnerability to stress and
reponse to antidepressants. J. Neurosci. 32, 4092-4101 (2012).
60. Bombardier A, Beauchemin M, Gosselin N, Poirier J, De Beaumont L. altered episodic memory in introverted
young adults carry the BDNFMet allele. Int J Mol Sci 2016;17(11):1886.
61. Dincheva I, Glatt CE, Lee FS. Impact of BDNF Val66Met polymorphism on cognition: implications for behavioral
genetics. Neuroscientist 2012;18(5):439-51.
62. Dempster E. Toulopoulou T, McDonald C, Bramon E, Walshe M, Filbey F, et al. Association between BDNF val66
met genotype and episodic memory. Am J Med Genet B Neuropsychiatr Genet 2005;134B(1):73-5.
63. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolanchana BS, Bertolino A, et al. The BDNF val66met
polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell
2003;112(2):257-69.
64. Erickson KI, Banducci SE, Weinstein AM, Macdonald AW, Ferrell RE, Halder I, et al. The brain-derived
neurotrophic factor Val66Met polymorphism moderates an effect of physical activity on working memory
performance. Psychol Sci 2013;24(9):1770-9.
65. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotropic factor
val66met polymorphism affects human memory-related hippocampal activity and predicts memory
performance. J Neurosci 2003;23(17):6690-4.
66. Kambeitz JP, Bhattacharyya S, Kambeitz-Ilankovic LM, Valli I, Collier DA, McGuire P. Effect of BDNF val(66)met
polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev
2012;36(9):2165-77.
67. Poo MM. Neurotropins as synaptic modulators. Nat Rev Neurosci 2001;2(1):24-32.
68. Choquet H, Cavalcanti-Proenca C, Lecoeur C, Dina C, Cauchi S, Vaxillaire M, et al. The T-381C SNP in BNP gene
may be modestly associated with type 2 diabetes: an update meta-analysis in 49 279 subjects. Hum Mol Genet
2009;18(13):2495-501.
69. Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, Mahoney DW, Slusser JP, Heublein DM, et al. The effect of
brain-type natriuretic peptide single-nucleotide polymorphism re198389 on test characteristics of common
assays. May Clin Proc 2011;86(3):210-218.
70. Johansson A, Eriksson N, Lindholm D, Varenhorst C, James S, Syvänen AC, et al. Genome-wide association and
Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet
2016;25(7):1447-56.
71. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natriuretic peptide
pathway affects BNP levels. Cardiovasc Drugs Ther 2007;21(1):55-62.
72. Meirhaeghe A, Sandhu MS, McCarthy MI, de Groote P, Cottel D, Arveiler D, et al. Association between the T-381C
polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol
Genet 2007;16(11):1343-50.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
73. Musani SK, Fox ER, Kraja A, Bidulescu A, Lieb W, Lin W, et al, Genome-wide association analysis of plasma
B-type natriuretic peptide in blacks: the Jackson Heart Study. Circ Cardiovasc Genet 2015;8(1):122-30.
74. Pfister R, Sharp S, Luben R, Welsh P, Barroso I, et al. Mendelian randomization study of B-type natriuretic
peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med
2011;8(10):e1001112.
75. Seidelmann SB, Vardeny O, Claggett B, Yu B, Shah AM, Ballantyne CM, et al. An NPPB promoter polymorphism
associated with elevated N-terminal pro-B-type natriuretic peptide and lower blood pressure, hypertension, and
mortality. J Am Heart Assoc 2017;6(4). Pii: e005257. Doi:10.1161.
76. Takeishi Y, Toriyama S, Takabatake N, Shibata Y, Konta T, Emi M, et al. Linkage disequilibrium analyses of
natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem Biophys
Res Commun 2007;362(2):480-4.
77. Zhang Q, Gong FQ, Zhu WH, Xie CH, Zhang YY, Ying LY. Correlation between re198388 and rs198389
polymorphism in brain natriuretic peptide (NPPB) gene and susceptibility to congenital heart disease in a Chinese
population. Int J of Clin and Exper Med 2015;8(10):19162-19166.
78. Yoshimizu T, et al. Functional implications of a psychiatric risk variant within CACNA1Cin induced human
neurons. Mol. Psychiatry 20, 162-169 (2015)
79. Harrison PJ, Molecular neurobiological clues to the pathogenesis of bipolar disorder. Curr. Opin. Neurobiol. 36, 1-
6 (2016)
80. J. I. Nurnberger, Jr. et al., Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry 71,
657- 664 (2014).
81. M. A. Ferreira et al., Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in
bipolar disorder. Nat. Genet. 40, 1056-1058 (2008).
82. S. Bhat et al., CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog. Neurobiol. 99, 1-14 (2012).
83. A. Szczepankiewicz, Evidence for single nucleotide polymorphisms and their association with bipolar disorder.
Neuropsychiatr Dis Treat 9, 1573-1582 (2013).
84. S. Gonzalez et al., Suggestive evidence for association between L-type voltage-gated calcium channel (CACNA1C)
gene haplotypes and bipolar disorder in Latinos: a family-based association study. Bipolar Disord. 15, 206-214
(2013).
85. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.
Nat Genet. 43, 977-983 (2011).
86. S. Erk et al., Replication of brain function effects of a genome-wide supported psychiatric risk variant in the
CACNA1C gene and new multi-locus effects. Neuroimage 94, 147-154 (2014).
87. J. L. Ivorra et al., Replication of previous genome-wide association studies of psychiatric diseases in a large
schizophrenia case-control sample from Spain. Schizophr. Res. 159, 107-113 (2014).
88. F. Nie et al., Genetic analysis of SNPs in CACNA1C and ANK3 gene with schizophrenia: A comprehensive meta-
analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168, 637-648 (2015).
89. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a
comprehensive meta-analysis of randomized clinical trials. PLoS ONE. 2014;9(5):e96905.
90. L. D. Brewer et al., Increased vulnerability of hippocampal neurons with age in culture: temporal association with
increases in NMDA receptor current, NR2A subunit expression and recruitment of L-type calcium channels. Brain
Res. 1151, 20-31 (2007).
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
91. F. M. Paulus et al., Association of rs1006737 in CACNA1C with alterations in prefrontal activation and fronto-
hippocampal connectivity. Hum. Brain Mapp. 35, 1190-1200 (2014).
92. C. Wolf et al., CACNA1C genotype explains interindividual differences in amygdala volume among patients with
schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 264, 93-102 (2014).
93. Dietsche B, Backes H, Laneri D, Weikert T, Witt SH, Rietschel M, et al. The impact of a CACNA1C gene
polymorphism on learing and hippocampal formation in healthy individuals: a diffusion tensor imaging study.
Neuroimage 2014;89:256-61.
94. Frazier TW, Youngstrom EA, Frankel BA, Zunta-Soares GB, Sanches M, Escamill M, et al. Candidate gene
associations with mood disorder cognitive vulnerability, and fronto-limbin volumes. Brain Behav 2014;4(3):418-
30.
95. Thimm M, Kircher T, Kellermann T, Markov V, Krach S, Jansen A, et al. Effects of a CACNA1C genotype on
attention networks in healthy individuals. Psychol Med 2011;41(7):1551-61.
96. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer’s disease risk gene CD33
inhibits microglial uptake of amyloid beta. Neuron 2013;78(4):631-43
97. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated
with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-41.
98. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP
are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429-35
99. Lambert JC, Ibrahim-verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new
susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-8.
100. Li X, Shen N, Zhang S, et al. CD33 rs3865444 Polymorphism Contributes to Alzheimer's Disease Susceptibility in
Chinese, European, and North American Populations. Mol Neurobiol. 2015;52(1):414-21.
101. Carrasquillo MM, Belbin O, Hunter TA, et al. Replication of EPHA1 and CD33 associations with late-onset
Alzheimer's disease: a multi-centre case-control study. Mol Neurodegener. 2011;6(1):54.
102. Saccone, Scott F., et al. "Cholinergic nicotinic receptor genes implicated in a nicotine dependence association
study targeting 348 candidate genes with 3713 SNPs." Human molecular genetics 16.1 (2006): 36-49.
103. Bierut, Laura Jean, et al. "Variants in nicotinic receptors and risk for nicotine dependence." American Journal of
Psychiatry 165.9 (2008): 1163-1171.
104. Tobacco and Genetics Consortium. "Genome-wide meta-analyses identify multiple loci associated with smoking
behavior." Nature genetics 42.5 (2010): 441-447.
105. Wang, Jen C., et al. "Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and
amino acid change in CHRNA5." Human molecular genetics 18.16 (2009): 3125-3135.
106. Saccone, Nancy L., et al. "Multiple independent loci at chromosome 15q25. 1 affect smoking quantity: a meta-
analysis and comparison with lung cancer and COPD." PLoS genetics 6.8 (2010): e1001053.
107. Chen, Li-Shiun, et al. "Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in
smoking cessation success." American Journal of Psychiatry 169.7 (2012): 735-742.
108. Stevens, Victoria L., et al. "Nicotinic receptor gene variants influence susceptibility to heavy smoking." Cancer
Epidemiology and Prevention Biomarkers 17.12 (2008): 3517-3525.
109. Valladares M, Obregón AM, Chaput JP. Association between genetic variants of the clock gene and obesity and
sleep duration. J Physiol Biochem. 2015;71(4):855-60.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
110. Shi SQ, White MJ, Borsetti HM, et al. Molecular analyses of circadian gene variants reveal sex-dependent links
between depression and clocks. Transl Psychiatry. 2016;6:e748.
111. Ozburn AR, Purohit K, Parekh PK, et al. Functional Implications of the CLOCK 3111T/C Single-Nucleotide
Polymorphism. Front Psychiatry. 2016;7:67.
112. Garaulet M, Lee YC, Shen J, Parnell LD, Arnett DK, TsaiMY et al (2009) CLOCK genetic variation and metabolic
syndrome risk: modulation by monounsaturated fatty acids. Am J Clin Nutr 90:1466–1475
113. Garaulet M, Corbalán MD, Madrid JA, Morales E, Baraza JC, Lee YC et al (2010) CLOCK gene is implicated in
weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. Int J
Obes (Lond) 34:516–523
114. Scott EM, Carter AM, Grant PJ (2008) Association between polymorphisms in the Clock gene, obesity and the
metabolic syndrome in man. Int J Obes (Lond) 32:658–662
115. Riestra P, Gebreab SY, Xu R, et al. Circadian CLOCK gene polymorphisms in relation to sleep patterns and obesity
in African Americans: findings from the Jackson heart study. BMC Genet. 2017;18(1):58.
116. Uemura H, Katsuura-kamano S, Yamaguchi M, et al. Variant of the clock circadian regulator (CLOCK) gene and
related haplotypes are associated with the prevalence of type 2 diabetes in the Japanese population. J Diabetes.
2016;8(5):667-76.
117. López-guimerà G, Dashti HS, Smith CE, Sánchez-carracedo D, Ordovas JM, Garaulet M. CLOCK 3111 T/C SNP
interacts with emotional eating behavior for weight-loss in a Mediterranean population. PLoS ONE.
2014;9(6):e99152.
118. Bandín C, Martinez-Nicolas A, Ordovás JM, Ros Lucas JA, Castell P, Silvente T et al (2013) Differences in circadian
rhythmicity in CLOCK 3111T/C genetic variants in moderate obese women as assessed by thermometry,
actimetry and body position. Int J Obes (Lond) 37:1044–1150
119. Mishima K, Tozawa T, Satoh K, Saitoh H, Mishima Y (2005) The 3111T/C polymorphism of hClock is associated
with evening preference and delayed sleep timing in a Japanese population sample. Am J Med Genet B
Neuropsychiatr Genet 133:101–104.
120. Garaulet M, Sánchez-moreno C, Smith CE, Lee YC, Nicolás F, Ordovás JM. Ghrelin, sleep reduction and evening
preference: relationships to CLOCK 3111 T/C SNP and weight loss. PLoS ONE. 2011;6(2):e17435.
121. Dashti HS, Follis JL, Smith CE, et al. Gene-Environment Interactions of Circadian-Related Genes for
Cardiometabolic Traits. Diabetes Care. 2015;38(8):1456-66.
122. Giovaninni NP, Fuly JT, Moraes LI, Coutinho TN, Trarbach EB, Jorge AA et al (2014) Study of the association
between 3111T/C polymorphism of the CLOCK gene and the presence of overweight in schoolchildren. J Pediatr
(Rio J) 90:500–505
123. A. J. Sheldrick et al., Effect of COMT val158met genotype on cognition and personality. Eur. Psychiatry 23, 385-
389 (2008).
124. M. J. Frank, et al., Neurogenetics and pharmacology of learning, motivation, and cognition.
Neuropsychopharmacology 36, 133-152 (2011).
125. J. H. Barnett, et al., Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive
function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol. Psychiatry
12, 502-509 (2007).
126. R. Cools, et al., Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol.
Psychiatry 69, e113-125 (2011).
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
127. R. Cools, Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14, 381-395
(2008).
128. J. A. Apud, et al., Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-
methyltransferase inhibitors. CNS Drugs 21, 535-557 (2007).
129. Andrews SJ, Das D, Cherbuin N, Ansley KJ, Easteal S. Association of genetic risk factors with cognitive decline: the
PATH through life project. Neurobiol Aging 2016;41:150-8.
130. Biehl SC, Gschwentner KM, Guhn A, Muller LD, Reichert S, Heupel J, Reif A, et al. Does adult ADHD interact with
COMT val (158) met genotype to influence working memory performance? Atten Defic Hyperact Disord
2015;7(1):19-25.
131. Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman JM, et al. Catechol-O-methyltransferase (COMT)
genotypes and working memory: association with differing cognitive operations. Biol Psychiatry
2005;58(11):901-7.
132. Fiocco AJ, Lindquist K, Ferrell R, Li R, Simonsick EM, Nalls M, et al. COMT genotype and cognitive function: an 8-
year longitudinal study in white and black elders. Neurology 2010;74(16):1296-302.
133. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, et al. Kinetics of human soluble and membrane-
bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the
enzyme. Biochemistry 1995;34(13):4202-10.
134. O’Donnell KJ, Glover V, Lahti J, Lahti M, Edgar RD, Räikkönen K, O’Connor TG. Maternal prenatal anxiety and child
COMT genotype predict working memory and symptoms for ADHD. PLoS One 2017;12(6):e0177506.
135. Pooley EC, Fineberg N, Harrison PJ. The met(158) allele of catechol-O-methyltransferase (COMT) is associated
with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol Psychiatry.
2007;12(6):556-61.
136. Kolassa IT, Kolassa S, Ertl V, Papassotiropoulos A, De quervain DJ. The risk of posttraumatic stress disorder after
trauma depends on traumatic load and the catechol-o-methyltransferase Val(158)Met polymorphism. Biol
Psychiatry. 2010;67(4):304-8.
137. Boscarino JA, Erlich PM, Hoffman SN, Zhang X. Higher FKBP5, COMT, CHRNA5, and CRHR1 allele burdens are
associated with PTSD and interact with trauma exposure: implications for neuropsychiatric research and
treatment. Neuropsychiatr Dis Treat. 2012;8:131-9.
138. Guillot CR, Fanning JR, Liang T, Berman ME. COMT Associations with Disordered Gambling and Drinking
Measures. J Gambl Stud. 2015;31(2):513-24.
139. Fuge P, Aust S, Fan Y, Weigand A, Gärtner M, Feeser M, Bajbouj M, Grimm S. Interaction of early life stress and
corticotropin-releasing hormone receptor gene: effects on working memory. Biol Psychiatry 2014;76(11):888-94.
140. Mahon PB, Zandi PP, Potash JB, Nestadt G, Wand GS. Genetic association of FKBP5 and CRHR1 with cortisol
response to acute psychosocial stress in healthy adults. Psychopharmacology (Berl) 2013;227(2):231-41.
141. Tsigos C, Chrousos GP, Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J of
Psychosomatic Research 2002;53:865-71.
142. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment
with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis
reactivity. Biol Psychiatry 2009;66(7):681-5.
143. Bradley RG, Binder EB, Epstein MP, et al. Influence of child abuse on adult depression: moderation by the
corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry. 2008;65(2):190-200.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
144. Grimm S, Gärtner M, Fuge P, et al. Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene
modulates age effects on working memory. J Psychiatr Res. 2015;61:57-63.
145. Polanczyk G, Caspi A, Williams B, et al. Protective effect of CRHR1 gene variants on the development of adult
depression following childhood maltreatment: replication and extension. Arch Gen Psychiatry. 2009;66(9):978-
85.
146. Lawlor DA, Harbord RM, Timpson NJ, Lowe GD, Rumley A, Gaunt TR, et al, The association of C-reactive protein
and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637
participants.
147. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins
(pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.
148. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12.
149. Nakamura M, Ishibashi Y, Tanaka F, et al. Ability of B-Type Natriuretic Peptide Testing to Predict Cardioembolic
Stroke in the General Population - Comparisons With C-Reactive Protein and Urinary Albumin. Circ J. 2018;
150. Zacho J, Tybaerg-Hansen A, Jensen JS, Grande P, Sillesen H, et al. Genetically elevated C-reactive protein and
ischemic vascular disease. NEJM 2008;359:1897-1908.
151. Hernandez-Diaz, Y., C. A. Tovilla-Zarate, I. Juarez-Rojop, M. A. Banos-Gonzalez, M. E. Torres-Hernandez, M. L.
Lopez-Narvaez, T. G. Yanez-Rivera and T. B. Gonzalez-Castro (2015). "The role of gene variants of the
inflammatory markers CRP and TNF-alpha in cardiovascular heart disease: systematic review and meta-analysis."
Int J Clin Exp Med 8(8): 11958-11984.
152. Lee, C. C., N. C. You, Y. Song, Y. H. Hsu, J. Manson, L. Nathan, L. Tinker and S. Liu (2009). "Relation of genetic
variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the
Women's Health Initiative Observational Cohort." Clin Chem 55(2): 351-360.
153. Almeida, O. P., P. E. Norman, R. Allcock, F. van Bockxmeer, G. J. Hankey, K. Jamrozik and L. Flicker (2009).
"Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the
Health in Men Study." Int J Epidemiol 38(4): 1049-1059.
154. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, et al. Moderation of adult depression by a
polymorphism in the FKBP5 gene and childhood physical abuse in the general population.
Neuropsychopharmacology 2011;36(10):1982-91.
155. Koenen KC, Saxe G, Purcell S, et al. Polymorphisms in FKBP5 are associated with peritraumatic
dissociation in medically injured children. Mol Psychiatry. 2005;10(12):1058-9.
156. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of
affective and anxiety disorders. Psychoneuroendocrinology. 2009;34:S186-95.
157. Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of
posttraumatic stress disorder symptoms in adults. JAMA 2008;299:1291-1305
158. de Kloet ER, Karst H, Joels M. Corticosteroid hormones in the central stress response: quick-and-slow. Front.
Neuroendocrinol 2008;29:268–272.
159. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG. Squirrel monkey immunophilin FKBP51 Is a potent
inhibitor of glucocorticoid receptor binding. Endocrinology 2000;141:4107-1..
160. Jaaskelainen, T, Makkonen, H, Palvimo, JJ. Steroid upregulation of FKBP51 and its role in hormone signaling. Curr
Opin Pharmacol 2011;11:326–331.
161. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. Annu Rev Nutr. 1999;19:379-406.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
162. Tatro ET, Everall IP, Kaul M, Achim CL. Modulation of glucocorticoid receptor nuclear translocation in neurons by
immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain Res 2009;1286:1-12
163. Velders FP, Kuningas M, Kumari M, et al. Genetics of cortisol secretion and depressive symptoms: a candidate
gene and genome wide association approach. Psychoneuroendocrinology 2011;36(7):1053-61.
164. Welberg LAM, Seckl JR. Prenatal stress, glucocorticoids and the programming of the brain. J. Neuroendocrinol
2001;13:113–128.
165. Spencer KA. Developmental stress and social phenotypes: integrating neuroendocrine, behavioural
and evolutionary perspectives. Philos Trans R Soc Lond, B, Biol Sci. 2017;372(1727)
166. Zimmermann P, Brückl T, Nocon A, Pfister H, Binder EB, Uhr M, et al. Interaction of FKBP5 gene variants and
adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J
Psychiatry 2011;168(10):.doi:10.1176.
167. Yeo GS. The role of the FTO (Fat Mass and Obesity Related) locus in regulating body size and composition. Mol
Cell Endocrinol. 2014;397(1-2):34-41.
168. Corella D, Arnett DK, Tucker KL, et al. A high intake of saturated fatty acids strengthens the association between
the fat mass and obesity-associated gene and BMI. J Nutr. 2011;141(12):2219-25.
169. Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruolonen A, et al. Common variation in the FTO
gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes
2008;57(5):1419-26.
170. Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M. FTO gene polymorphisms and obesity risk: a meta-analysis. BMC Med
2011;9:71.
171. Phillips CM, Kesse-Guyot E, McManus R, Hercberg S, Lairon D, Planells R, Roche HM. High dietary saturated fat
intake accentuates obesity risks associated with the fat mass and obesity-associated gene in adults. J Nutr
2012;142(5):824-31.
172. Sjögren M, Lyssenko V, Jonsson A, Berlund G, Nilsson P, Groop L, et al. The search for putative unifying genetic
factors for components of the metabolic syndrome. Diabetologia 2008;51(12)2242-51.
173. Sonestedt E, Roos C, Gullberg B, Ericson U, Wirfält E, Orho-Melander M. Fat and carbohydrate intake modify the
association between genetic variation in the FTO genotype and obesity. Am J Clin Cutr 2009;90(5):1418-25.
174. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson Au, et al. Association analyses of 249,796
individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42(11):937-48.
175. Wang H, Dong S, Xu H, Qian J, Yang J. Genetic variants in FTO associated with metabolic syndrome: a meta- and
gene-based analysis. Mol Biol Rep 2012;39(5):5691-8.
176. Wardle J, Carnell S, Haworth CM, Faroogi IS, O’Rahilly S, Plomin R. Obesity associated genetic variation in FTO is
associated with diminished satiety.
177. Thomsen M, Dahl M, Tybjærg-hansen A, Nordestgaard BG. β2-adrenergic receptor Thr164Ile polymorphism,
obesity, and diabetes: comparison with FTO, MC4R, and TMEM18 polymorphisms in more than 64,000
individuals. J Clin Endocrinol Metab. 2012;97(6):E1074-9.
178. Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, et al, Extended analysis of a genome-wide
association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012;57(2):366-75.
179. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis
increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42(12):1118-25.
180. Hu DY, Shao XX, Xu CL, Xia SL, Yu LQ, et al. Associations of FUT2 and FUT3 gene polymorphisms with Crohn’s
disease in Chinese patients. J Gastroenterol Hepatol 2014;29(10):1778-85.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
181. McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, et al. Fucosyltransferase 2 (FUT2) non-
secretor status is associated with Crohn’s disease. Hum Mol Genet 2010;19(17):3468-76.
182. Parmar AS, Alakulppi N, Paavola-Sakki P, Kurppa K, Halme L, Fäkkilä M, et al. Association study of FUT2
(rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. Tissue Antigens
2012;80(6):488-93.
183. Rupp C, Friedrich K, Folseraas T, Wannhott A, Bode KA, et al. FUT2 genotype is a risk factor for dominant stenosis
and biliary candida infection in primary sclerosing cholangitis. Ailment Pharmacol Ther 2014;39(8):873-82.
184. Marionneau S, Cailleau-thomas A, Rocher J, et al. ABH and Lewis histo-blood group antigens, a model for the
meaning of oligosaccharide diversity in the face of a changing world. Biochimie. 2001;83(7):565-73.
185. Hazra A, Kraft P, Selhub J, et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat
Genet. 2008;40(10):1160-2.
186. Tong M, Mchardy I, Ruegger P, et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's
disease risk polymorphism. ISME J. 2014;8(11):2193-206.
187. Wacklin P, Mäkivuokko H, Alakulppi N, et al. Secretor genotype (FUT2 gene) is strongly associated with the
composition of Bifidobacteria in the human intestine. PLoS ONE. 2011;6(5):e20113.
188. Wacklin P, Tuimala J, Nikkilä J, et al. Faecal microbiota composition in adults is associated with the FUT2 gene
determining the secretor status. PLoS ONE. 2014;9(4):e94863.
189. Dichgans M, Malik R, König IR, Rosand J, Clarke R, et al. Shared genetic susceptibility to ischemic stroke and
coronary artery disease – a genome-wide analysis of common variants. Stroke 2014;45(1):24-36.
190. Han Y, Sun W, Wang L, Tao S, Tian L, Hao Y, et al. HDAC9 gene is associated with stroke risk in a Chinese
population. Exp Biol Med (Maywood) 2013;238(7):842-7.
191. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid
intima-media thickness: a systemic review and meta-analysis. Circulation 2007;115(4):459-67.
192. Markus HS, Mäkelä K-M, Bevan S, Raitoharju E, Oksala N, Bis JC, et al. Evidence HDAC9 genetic variant associated
with ischaemic stroke increase risk via promoting carotid atherosclerosis. Stroke 2013;44(5):1220-25.
193. Marcus HS, International Stroke Genetics Consortium and Wellcome Trust Case Control Consortium. Genome-
wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Benet
2012;44(3):328-333.
194. Mathiesen EB, Johnsen SH. Ultrasonographic measurements of subclinical carotid atherosclerosis in prediction of
ischemic stroke. Acta Neurol Scand Suppl 2009;189:68-72.
195. O’Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwant SJ, et al. Genome-wide association study for
coronary artery calcification with follow-up in myocardial infarction. Circulation 2011;124(25):2855-64.
196. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng Y-C. Genetic risk factors for ischaemic stroke and
its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet
Neurol 2012;11(11):951-62.
197. Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide association study identifies a variant in HDAC9
associated with large vessel ischemic stroke. Nat Genet. 2012;44(3):328-33.
198. Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology. 2005;128(4 Suppl
1):S68-73.
199. Leonard MM, Sapone A, Catassi C, Fasano A. Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA.
2017;318(7):647-656.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
200. Leonard MM, Serena G, Sturgeon C, Fasano A. Genetics and celiac disease: the importance of screening. Expert
Rev Gastroenterol Hepatol. 2015; 9(2):209-215.
201. Choo SY. The HLA System: Genetics, Immunology, Clinical Testing, and Clinical Implications. Yonsei Medical
Journal. 2007; 48(1):11-23.
202. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F and Thorsby E. Evidence for a primary association of celiac
disease to a particular HLA-DQ α/β heterodimer. J Exp Med. 1989; 169:345-350.
203. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A high-resolution HLA and SNP
haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006; 38(10):1166-72.
204. Monsuur AJ, de Bakker PI, Zhernakova A, Pinto D, Verduijn W, Romanos J, et al. Effective detection of human
leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphisms. PLoS One. 2008;
3(5):e2270. doi: 10.1371/journal.pone.0002270.
205. Walker MM1, Murray JA, Ronkainen J, Aro P, Storskrubb T, D'Amato M, et al. Detection of celiac disease and
lymphocytic enteropathy by parallel serology and histopathology in a population-based study. Gastroenterology.
2010; 139(1):112-9. doi: 10.1053/j.gastro.2010.04.007.
206. Castro-Antunes MM, Crovella S, Brandao LA, Guimaraes RL, Motta ME, Silva GA. Frequency distribution of HLA
DQ2 and DQ8 in celiac patients and first-degree relatives in Recife, northeastern Brazil. Clinics (Sao Paulo). 2011;
66(2):227-31.
207. Rostami-Nejad M, Romanos J, Rostami K, Ganji A, Ehsani-Ardakani MJ, Bakhshipour AR, et al. Allele and
haplotype frequencies for HLA-DQ in Iranian celiac disease patients. World J Gastroenterol. 2014; 20(20):6302-8.
doi: 10.3748/wjg.v20.i20.6302.
208. Bastos MD, Kowalski TW, Puñales M, Tschiedel B, Mariath LM, Pires ALG, et al. Search for DQ2.5 and DQ8 alleles
using a lower cost technique in patients with type 1 diabetes and celiac disease in a population of southern
Brazil. Arch Endocrinol Metab. 2017; 13:0. doi: 10.1590/2359-3997000000282
209. Almeida LM, Gandolfi L, Pratesi R, Uenishi RH, de Almeida FC, Selleski N, et al. Presence of DQ2.2 Associated with
DQ2.5 Increases the Risk for Celiac Disease. Autoimmune Dis. 2016; 2016:5409653. doi: 10.1155/2016/5409653.
210. Van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, et al. A genome-wide association study for
celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet. 2007; 39(7): 827–829.
211. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease
influencing immune gene expression. Nat Genet. 2010; 42(4):295-302. doi: 10.1038/ng.543.
212. Tafti, Mehdi, et al. "Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity." Sleep 39.3
(2016): 581-587.
213. Mahlios, Josh, Alberto K. De la Herrán-Arita, and Emmanuel Mignot. "The autoimmune basis of
narcolepsy." Current opinion in neurobiology 23.5 (2013): 767-773.
214. Tafti, Mehdi, et al. "DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in
Europe." Sleep 37.1 (2014): 19-25.
215. Mignot, E., et al. "HLA DQB1* 0602 is associated with cataplexy in 509 narcoleptic patients." Sleep 20.11 (1997):
1012-1020.
216. Rogers, A. E., et al. "HLA DR15 (DR2) and DQB1* 0602 typing studies in 188 narcoleptic patients with
cataplexy." Neurology 48.6 (1997): 1550-1556.
217. Chabas, Dorothée, et al. "The genetics of narcolepsy." Annual review of genomics and human genetics 4.1
(2003): 459-483.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
218. Mignot, Emmanuel, et al. "Complex HLA-DR and-DQ interactions confer risk of narcolepsy-cataplexy in three
ethnic groups." The American Journal of Human Genetics 68.3 (2001): 686-699.
219. Fernandez, O., et al. "DQB1* 0602 allele shows a strong association with multiple sclerosis in patients in Malaga,
Spain." Journal of neurology 251.4 (2004): 440-444.
220. J. W. Stephens, S. J. Hurel, J. A. Cooper, J. Acharya, G. J. Miller, and S. E. Humphries, “A common functional
variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes
mellitus,” Molecular Genetics and Metabolism, vol. 82, no. 2, pp. 180– 186, 2004.
221. P. C. Heinrich, J. V. Castell, and T. Andus, “Interleukin-6 and the acute phase response,” Biochemical Journal, vol.
265, no. 3, pp. 621–636, 1990.
222. Pedersen BK, Febbraio MA (Oct 2008). "Muscle as an endocrine organ: focus on muscle-derived interleukin-6".
Physiological Reviews. 88 (4): 1379–406.
223. A. Steensberg, C. P. Fischer, C. Keller, K. Møller, and B. K. Pedersen, “IL-6 enhances plasma IL 1ra, IL-10, and
cortisol in humans,” American Journal of Physiology, vol. 285, no. 2, pp. E433–E437, 2003.
224. L. Ghazouani, N. Abboud, S. B. H. Khalifa et al., “-174G>C interleukin-6 gene polymorphism in Tunisian patients
with coronary artery disease,” Annals of Saudi Medicine, vol. 31, no. 1, pp. 40–44, 2011.
225. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6
transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin
Invest. 1998;102(7):1369-76.
226. Mansoori N, Tripathi M, Luthra K, et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of
Alzheimer's and vascular dementia and their epistatic interaction. Neurobiol Aging. 2012;33(5):1003.e1-8.
227. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: A systematic review and meta-
analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine. 2017;99:132-138.
228. Franklin AL, Said M, Cappiello CD, et al. Are Immune Modulating Single Nucleotide Polymorphisms Associated
with Necrotizing Enterocolitis?. Sci Rep. 2015;5:18369.
229. Bower JE, Ganz PA, Irwin MR, Castellon S, Arevalo J, Cole SW. Cytokine genetic variations and fatigue among
patients with breast cancer. J Clin Oncol. 2013;31(13):1656-61.
230. Zhu J, Guo B, Fu M, et al. Interleukin-6-174G/C Polymorphism Contributes to Periodontitis Susceptibility: An
Updated Meta-Analysis of 21 Case-Control Studies. Dis Markers. 2016;2016:9612421.
231. Mancini, M., Grappasonni, I., Scuri, S., and Amenta, F. (2010). Oral health in Alzheimer’s disease: a review. Curr.
Alzheimer Res. 7, 368–373.
232. Gaur, S., and Agnihotri, R. (2015). Alzheimer’s disease and chronic periodontitis: is there an association? Geriatr.
Gerontol. Int. 15, 391–404.
233. Teixeira FB, Saito MT, Matheus FC, et al. Periodontitis and Alzheimer's Disease: A Possible Comorbidity between
Oral Chronic Inflammatory Condition and Neuroinflammation. Front Aging Neurosci. 2017;9:327.
234. Antilla V, Winsvold BS, Gormely P, Kurth T, Bettella F, McMahon G, et al. Genome-wide meta-analysis identifies
new susceptibility loci for migraine. Nat Genet 2013;45(8):912-17.
235. Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, et al. Genome-wide association study of
migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42(10):869-73.
236. Chasman DI, Antilla V, Buring JE, Ridker PM, Schürks M, Kurth T, et al. Selectivity in genetic association with sub-
classified migraine in women. PLoS Genet 2014;10(5):e1004366.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
237. Chasman DI, Schürks M, Anttila V, de Vries B, Schminke U, Launer LJ, et al. Genome-wide study reveals three
susceptibility loci for common migraine in the general population. Nat Genet 2011;43(7):695-98.
238. Esserlind AL, Christensen AF, Steinberg S, Grarup N, Pedersen O, Hansen T, et al. The association between
candidate migraine susceptibility loci and severe migraine phenotype in a clinical sample. Cephalagia
2016;36(7):615-23.
239. Esserlind AL, Christensen AF, Le H, Kirchmann M, Hauge AW, Toyserkani NM, Replication and meta-analysis of
common variants identifies a genome-wide significant locus in migraine. Eur J Neurol 2013;20(5):765-72.
240. Freilinger T, Antilla V, de Vries B, Malik R, Kallela M, Terwindt GM, Pozo-Rosich P, et al. Nat Genet
2012;44(7):777-82.
241. Harriott AM, Heckman MG, Rayaprolu S, et al. Low density lipoprotein receptor related protein 1 and 6 gene
variants and ischaemic stroke risk. Eur J Neurol. 2015;22(8):1235-41.
242. Lillis AP, Van duyn LB, Murphy-ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific
functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887-918.
243. Guo DC, Grove ML, Prakash SK, et al. Genetic Variants in LRP1 and ULK4 Are Associated with Acute Aortic
Dissections. Am J Hum Genet. 2016;99(3):762-769.
244. Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, et al. Mutations in LRRK2 increase phosphorylation of
peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 2011;32(12):1390-7.
245. Benitez BA, Davis AA, Jin SC, Ibanez L, Ortega-Cubero S, Choi J, et al. Resequencing analysis of five Mendelian
genes and the top genes from genome-wide association study in Parkinson’s disease. Mol Neurodegener
2016;11:29.
246. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, et al. Web-based genome-wide association study
identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet
2011;7(6):e1002141.
247. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, ross OA, Lynch T, et al. Identification of a
novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across
European populations. Am J Hum Genet 2005;76(4):672-80.
248. Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simón-Sánchez J, et al. Using genome-wide complex trait
analysis to quantify “missing heritability” in Parkinson’s disease. Hum Mol Genet 2012;21(22):4996-5009.
249. Zimprich A, Biskup S, Leitner P, Farrer M, Lincoln S, Kacherqus J, et al. Mutations in LRRK2 cause autosomal-
dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):610-7.
250. Farooqi IS, Yeo GSH, Keogh JM, Aminian S, Jabb SA, Butler G, et al. Dominant and recessive inheritance of morbid
obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000;106(2):271-279.
251. Loos RJ, Lindgren CM, Li S, Wheeler E, Ahao JH, Prokopenki I, et al. Common variants near MC4R are associated
with fat mass, weight, and risk of obesity. Nat Genet 2008;40(6):768-75.
252. Qi L, Kraft P, Hunter DJ, Hu FB. The common obesity variant near MC4R gene is associated with higher intakes of
total energy and dietary fat, weight change and diabetes risk in women. Hum Mol Genet. 2008;17(22):3502-8.
253. Zobel DP, Andreasen CH, Grarup N, et al. Variants near MC4R are associated with obesity and influence obesity-
related quantitative traits in a population of middle-aged people: studies of 14,940 Danes. Diabetes.
2009;58(3):757-64.
254. He M, Xu M, Zhang B, et al. Meta-analysis of genome-wide association studies of adult height in East Asians
identifies 17 novel loci. Hum Mol Genet. 2015;24(6):1791-800.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
255. Graff M, Scott RA, Justice AE, et al. Genome-wide physical activity interactions in adiposity - A meta-analysis
of 200,452 adults. PLoS Genet. 2017;13(4):e1006528.
256. Ortega-azorín C, Sorlí JV, Asensio EM, et al. Associations of the FTO rs9939609 and the MC4R rs17782313
polymorphisms with type 2 diabetes are modulated by diet, being higher when adherence to the Mediterranean
diet pattern is low. Cardiovasc Diabetol. 2012;11:137.
257. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, et al. Restless legs syndrome: diagnostic criteria,
special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology
workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
258. Haba-Rubio J, Marti-Soler H, Marques-Vidal P, Tobback N, Andries D, Preisig M, et al. Prevalence and
determinants of periodic limb movements in the general population. Ann Neurol 2016;79(3):464-74.
259. Kemlink D, Polo O, Frauscher B, Gschliesser V, Högl B, Poewe W, et al. Replication of restless legs syndrome loci
in three European populations. J Med Genet 2009;46(5):315-18.
260. Moore H, Winkelmann J, Lin L, Finn L, Peppard P, Mignot E. Periodic leg movements during sleep are associated
with polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD. Sleep 2014;37(9):1535-42.
261. Shen Y, Liu H, Dai T, Guan Y, Tu J, Nie H. Association between restless legs syndrome and hypertension: a meta-
analysis of nine population-based studies. Neurol Sci. 2017;
262. Spieler D, Kaffe M, Knauf F, Bessa J, Tena JJ, Giesert F, et al. Restless legs syndrome-associated intronic common
variant in Meis1 alters enhancer function in the developing telencephalon. Genome Res 2014;24(4):592-603.
263. Winkelmann JW, Blackwell T, Stone K, Ancoli-Israel S, Tranah GJ, Redline S, et al. Genetic association of periodic
limb movements of sleep in the elderly, for the MrOS sleep study. Sleep Med 2015;16(11):1360-65.
264. Winkelmann J, Schomair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of
restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39(8):1000-6.
265. Xiong L, Catoire H, Dion P, Gaspar C, Lafreniére RG, Girard SL, et al. MEIS1 intronic risk haplotype associated with
restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet 2009;18(6):1065-74.
266. Yang Q, Li L, Chen Q, Foldvary-Schaefer N, Ondo WG, Wang QK. Association studies of variants in MEIS1, BTBD9,
and MAP2K5/SKOR1 with restless legs syndrome in a US population. Sleep Med 2011;12(8):800-4.
267. Hu Z, Li Z. miRNAs in synapse development and synaptic plasticity. Curr Opin Neurobiol 2017;45:24-31.
268. Lancaster TM, Ihssen N, Brindley LM, Linden DEJ. Further support for association between GWAS variant for
positive emotion and reward systems. Transl Psychiatry 2017;7(1):e1018.
269. Wingo AP, Almli LM, Stevens JS, et al. Genome-wide association study of positive emotion identifies a genetic
variant and a role for microRNAs. Mol Psychiatry. 2017;22(5):774-783.
270. Li QJ, Chau J, Ebert PJ, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell.
2007;129(1):147-61.
271. Saba R, Störchel PH, Aksoy-aksel A, et al. Dopamine-regulated microRNA MiR-181a controls GluA2 surface
expression in hippocampal neurons. Mol Cell Biol. 2012;32(3):619-32.
272. De Neve JE, Oswald AJ. Estimating the influence of life satisfaction and positive affect on later income using
sibling fixed effects. Proc Natl Acad Sci USA 2012; 109:19953–19958.
273. Chida Y, Steptoe A. Positive psychological well-being and mortality: a quantitative review of prospective
observational studies. Psychosom Med 2008; 70: 741–756
274. Zautra AJ, Johnson LM, Davis MC. Positive affect as a source of resilience for women in chronic pain. J Consult
Clin Psychol 2005; 73: 212–220.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
275. Stahl SM., L-methylfolate: a vitamin for your monoamines. J. Clin. Psychiatry 69, 1352-1353 (2008).
276. Wu YL. Association between MTHFR C677T polymorphism and depression: An updated meta-analysis of 26
studies. Prog Neuropsychopharmacol. Biol. Psychiatry 46 78-85 (2013).
277. Gilbody, et al. Methylenetetrahydrofolate reduactase (MTHFR) genetic polymorphisms and psychiatric disorders:
a HuGE review. Am J. Epidemiol. 165, 1-13 (2007).
278. Papakostas GI et al., L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two
randomized, double-blind, parallel-sequential trials. Am J. Psychiatry 169 1267-1274 (2012)
279. Ginsberg LD, et al. L-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI
monotherapy in a major depressive episode. Innov Clin Neurosci 8 19-28 (2011).
280. Wade RL, et al. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients
with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy. Journal of
managed care pharmacy. JCMP 20 76-85 (2014)
281. Papakostas et al., Effect of adjunctive L-methylfolate 15mg among inadequate responders to SSRIs in depressed
patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. Clin
Psychiatry 75 855-863 (2014).
282. Mech AW, et al. Correlation of clinical response with homocysteine reduction during therapy with reduced B
vitamins in patients with MDD who are positive for MTHFR C^77T polymorphism: epidemiology, metabolism and
the associated diseases. Eur J. Med. Genet. 58 1-10 (2015).
283. Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology,
metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1-10.
284. Bradley B, Davis TA, Wingo AP, Mercer KB, Ressler KJ. Family environment and adult resilience: contribution of
positive parenting and the oxytocin receptor gene. Eur J Psychotraumatol 2013;4:10.3402.
285. Bradley B, Westen D, Mercer KB, Binder EB, Jovanovic T, Crain D, et al. Association between childhood
maltreatment and adult emotional dysregulation in a low-income, urban, African American sample: moderation
by oxytocin receptor gene. Dev Psychopathol 2011;23(2):439-52.
286. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 2008;322:900-4.
287. Gong P, Fan H, Liu J, Yang X, Zhang K, Zhou X. Revisiting the impact of OXTR rs53576 on empathy: a population-
based study and a meta-analysis. Psychoneuroendocrinology 2017;80:131-36.
288. Hostinar CE, Cicchetti D, Roqosch FA. Oxytocin receptor gene polymorphism, perceived social support, and
psychological symptoms in maltreated adolescents. Dev Psychopathol 2014;26(2):465-77.
289. Li J, Zhao Y, Li R, Broster LS, Zhou C, Yang S. Association of oxytocin receptor genet (OXTR) rs53576
polymorphism with sociality: a meta-analysis. PLoS One 2015;10(6):e0131820.
290. Mcquaid RJ, Mcinnis OA, Stead JD, Matheson K, Anisman H. A paradoxical association of an oxytocin receptor
gene polymorphism: early-life adversity and vulnerability to depression. Front Neurosci. 2013;7:128.
291. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs > Oxytocin and vasopressin in the human brain: social
neuropeptides for translational medicine. Nat Rev Neurosci 2011;12:524-38.
292. Moons WG, Way BM, Taylor SE. Oxytocin and vasopressin receptor polymorphisms interact with circulating
neuropeptides to predict human emotional reactions to stress. Emotion 2014;14(3):562-72.
293. Poulin MJ, Holman EA. Helping hands, healthy body? Oxytocin receptor gene and prosocial behavior interact to
buffer the association between stress and physical health. Horm Behav 2013;63(3):510-7.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
294. Smearman EL, Winiarski DA, Brennan PA, Najman J, Johnson KC. Social stress and the oxytocin receptor gene
interact to predict antisocial behavior in an at-risk cohort. Dev Psychopathol 2015;27(1):309-18.
295. Sturge-Apple ML, Cicchetti D, Davies PT, Suor JH. Differential susceptibility in spillover between interparental
conflict and maternal parenting practices: evidence for OXTR and 5-HTT genes. J Fam Psychol 2012;26(3):431-42.
296. Abifadel M, Varret M, Rabès JP, Allard D, Ouquerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal
dominant hypercholersterolemia, Nat Genet 2003;34(2):154-6.
297. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and
coronary artery disease risk in 16 European population cohorts. Nat Genet 2009;41(1):47-55.
298. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis
identifies new risk loci for coronary artery disease. Nat Genet 2013;45(1):25-33.
299. Guella I, Asselta R, Ardissino D, Merlini PA, Peyvandi F, Kathiresan S, et al. Effects of PCSK9 genetic variants on
plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J Lipid Res
2010;51(11):3342-9.
300. Gupta R, Ejebe K, Butler J, et al. Association of common DNA sequence variants at 33 genetic loci with blood
lipids in individuals of African ancestry from Jamaica. Hum Genet. 2010;128(5):557-61
301. Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking
therapy of lipid disorders in one decade. Arch Med Sci. 2017;13(4):914-929.
302. Joseph L, Robinson JG. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid
Lowering Therapy. Prog Cardiovasc Dis. 2015;58(1):19-31.
303. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-
density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet
2008;40(2):189-97.
304. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, et al. A spectrum of PC SK9 alleles contributes
to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006;78(3):410-22.
305. Murray A, Cluett C, Bandinelli S, Corsi AM, Ferrucci L, Guralnik J, Singleton A, et al. Common lipid-altering gene
variants are associated with therapeutic intervention thresholds of lipid levels in older people. Eur Heart J
2009;30(14):1711-9.
306. Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid levels and risk of coronary
artery disease. Arterioscler Thromb Vasc Biol. 2010;30(11):2264-76.
307. Weinreich M, Frishman WH. Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev. 2014;22(3):140-6.
308. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid
concentrations and risk of coronary artery disease. Nat Genet 2008;40(2):161-9.
309. Xu C, Wang F, Wang B, et al. Minor allele C of chromosome 1p32 single nucleotide polymorphism rs11206510
confers risk of ischemic stroke in the Chinese Han population. Stroke. 2010;41(8):1587-92.
310. Chandra M, Miriyala S, Panchatcharam M. PPARγ and Its Role in Cardiovascular Diseases. PPAR Res.
2017;2017:6404638.
311. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated
transcription factor. Cell. 1994; 79(7):1147-56. [PMID 8001151]
312. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in
PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin
sensitivity. Nat Genet. 1998; 20(3):284-7. doi:10.1038/3099
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
313. Chan KH, Niu T, Ma Y, You NC, Song Y, Sobel EM, et al. Common genetic variants in peroxisome proliferator-
activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal
women. J Clin Endocrinol Metab. 2013 Mar;98(3):E600-4. doi: 10.1210/jc.2012-3644. [PMID 23386649]
314. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may
confer resistance to type 2 diabetes. Biochem Biophys Res Commun. 2000; 271(1):212-6.
doi:10.1006/bbrc.2000.2605 [PMID 10777704]
315. Pei Q, Huang Q, Yang GP, Zhao YC, Yin JY, Song M, et al. PPAR-γ2 and PTPRD gene polymorphisms influence type
2 diabetes patients' response to pioglitazone in China. Acta Pharmacol Sin. 2013; 34(2):255-61. doi:
10.1038/aps.2012.144. [PMID 23147557]
316. Wu L, Cui L, Tam WH, Ma RC, Wang CC. Genetic variants associated with gestational diabetes mellitus: a meta-
analysis and subgroup analysis. Sci Rep. 2016; 6:30539. doi: 10.1038/srep30539. [PMID 27468700]
317. Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-
activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals.
Diabetes Care. 2006; 29(11):2489-97.
318. Galbete C, Toledo E, Martínez-González MA, Martínez JA, Guillén-Grima F, Marti A. Pro12Ala variant of the
PPARG2 gene increases body mass index: An updated meta-analysis encompassing 49,092 subjects. Obesity
(Silver Spring). 2013; 21(7):1486-95.
319. Masud S, Ye S; SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala
variant on body mass index: a meta-analysis. J Med Genet. 2003 Oct;40(10):773-80.
320. Passaro A, Dalla Nora E, Marcello C, Di Vece F, Morieri ML, Sanz JM, et al. PPARγ Pro12Ala and ACE ID
polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome. Cardiovasc Diabetol.
2011 Dec 14;10:112. doi: 10.1186/1475-2840-10-112.
321. Zarebska A, Jastrzebski Z, Cieszczyk P, Leonska-Duniec A, Kotarska K, Kaczmarczyk M, et al. The Pro12Ala
Polymorphism of the Peroxisome Proliferator-Activated Receptor Gamma Gene Modifies the Association of
Physical Activity and Body Mass Changes in Polish Women. PPAR Res. 2014; (2014):373782. doi:
10.1155/2014/373782.
322. Aller EEJG, Mariman ECM, Bouwman FG, van Baak MA. Genetic Predictors of ≥5% Weight Loss by
Multidisciplinary Advice to Severely Obese Subjects. J Nutrigenet Nutrigenomics. 2017; 10(1-2):32-42. doi:
10.1159/000469662.
323. García-Calzón S, Martínez-González MA, Razquin C, Corella D1, Salas-Salvadó J, Martínez JA, et al. Pro12Ala
polymorphism of the PPARγ2 gene interacts with a mediterranean diet to prevent telomere shortening in the
PREDIMED-NAVARRA randomized trial. Circ Cardiovasc Genet. 2015; 8(1):91-9. doi:
10.1161/CIRCGENETICS.114.000635. [PMID 25406242]
324. Davies RW, Dandona S, Stewart AFR, Chen L, Ellis SG, Tang WHW, et al. Improved prediction of cardiovascular
disease based on a panel of single nucleotide polymorphisms identified through genome-wide association
studies. Circ Cardiovasc Genet 2010;3(50):468-74.
325. Franceschini N, Hu Y, Reiner AP, et al. Prospective associations of coronary heart disease loci in African
Americans using the MetaboChip: the PAGE study. PLoS ONE. 2014;9(12):e113203.
326. Heckman MG, Soto-ortolaza AI, Diehl NN, et al. Genetic variants associated with myocardial infarction in the
PSMA6 gene and Chr9p21 are also associated with ischaemic stroke. Eur J Neurol. 2013;20(2):300-8.
327. Jamaldini SH, Babanejad M, Mozaffari R, et al. Association of polymorphisms at LDLR locus with coronary artery
disease independently from lipid profile. Acta Med Iran. 2014;52(5):352-9.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
328. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM. Genome-wide association of
early-onset myocardial infarction with common single nucleotide polymorphisms, common copy number
variants, and rare copy number variants. Nat Genet 2009;41(3):334-41.
329. Liu S, Xiu B, Liu J, et al. Association of rs1122608 with Coronary Artery Disease and Lipid Profile: A Meta-analysis.
Arch Med Res. 2016;47(4):315-20.
330. Martinelli N, Girelli D, Lunghi B, Pinotti M, Marchetti G, Malerba G, et al. Polymorphisms at LDLR locus may be
associated with coronary artery disease through modulation of coagulation factor VIII activity and independently
from lipid profile. Blood 2010;116(25):5688-97.
331. Van iperen EP, Sivapalaratnam S, Boekholdt SM, et al. Common genetic variants do not associate with CAD in
familial hypercholesterolemia. Eur J Hum Genet. 2014;22(6):809-13.
332. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and
association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide
association studies. Lancet. 2011;377(9763):383-92.
333. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score
for coronary artery disease: case-control and prospective cohort analyses. Lancet 2010;376(9750):1393-400.
334. Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for
coronary artery disease. Nat Genet. 2011;43(4):333-8.
335. Xiong X, Chenqqi X, Zhang Y, Li X, Wang B, Wang F, et al. BRG1 variant re1122608 on chromosome 19p13.2
confers protection against stroke and regulates expression of pre-mRNA-splicing factor SFRS3. Hum Genet
2014;133(5):499-508.
336. Van de Woestijne AP, van der Graaf Y, de Bakker PI, Asselbergs FW, de Borst GJ, Algra A, et al. LDL-c-linked SNPs
are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established
vascular disease. Eur J Clin Invest 2014;44(2):184-91.
337. Zhang L, Yuan F, Liu P, et al. Association between PCSK9 and LDLR gene polymorphisms with coronary heart
disease: case-control study and meta-analysis. Clin Biochem. 2013;46(9):727-32.
338. Wang Y, Wang L, Liu X, et al. Genetic variants associated with myocardial infarction and the risk factors in
Chinese population. PLoS ONE. 2014;9(1):e86332.
339. Murabito JM, White CC, Kavousi M, et al. Association between chromosome 9p21 variants and the ankle-brachial
index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet. 2012;5(1):100-
12.
340. Gonzalez J, Schmutz C, Munger C, Perkes A, Gustin A, Peterson M, et al. Assessment of TREM2 R47H association
with Alzheimer’s disease in a population-based sample: The Cache County Study. Neurobiol Aging
2013;34(12):2889.e11-2889.
341. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Roqaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s
disease; NEJM 2013;368(2):117-27.
342. Huang M, Wang D, Xu Z, Xu Y, Xu X, Ma Y, et al. Lack of genetic association between TREM2 and Alzheimer’s
disease in East Asian population: a systemic review and meta-analysis. Am J Alzheimers Dis Other Demen
2015;30(6):541-6.
343. Painter MM, Ataqi Y, Liu CC, Rademakers R, Xu H, Fryer JD, et al. TREM2 in CNS homeostasis and
neurodegenerative disease. Mol Neurodegener 2015;10:43.
344. Paloneva J, Mannienen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al. Mutations in two genes
encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum
Genet 2002; 71(3):656-662.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
345. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the
microglial response in an Alzheimer’s disease model. Cell 2015;160(6):1061-71.
346. Nascimento CM, Pereira JR, Pires de andrade L, et al. Physical exercise improves peripheral BDNF levels and
cognitive functions in mild cognitive impairment elderly with different bdnf Val66Met genotypes. J Alzheimers
Dis. 2015;43(1):81-91.
347. Dinoff A, Herrmann N, Swardfager W, Lanctôt KL. The effect of acute exercise on blood concentrations of brain-
derived neurotrophic factor in healthy adults: a meta-analysis. Eur J Neurosci. 2017;46(1):1635-1646.
348. Celis-morales C, Marsaux CF, Livingstone KM, et al. Can genetic-based advice help you lose weight? Findings from
the Food4Me European randomized controlled trial. Am J Clin Nutr. 2017;105(5):1204-1213.
349. Bjørnland T, Langaas M, Grill V, Mostad IL. Assessing gene-environment interaction effects of FTO, MC4R and
lifestyle factors on obesity using an extreme phenotype sampling design: Results from the HUNT study. PLoS
ONE. 2017;12(4):e0175071.
350. Xiang L, Wu H, Pan A, et al. FTO genotype and weight loss in diet and lifestyle interventions: a systematic review
and meta-analysis. Am J Clin Nutr. 2016;103(4):1162-70.
351. Sindi S, Ngandu T, Hovatta I, et al. Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention
on Cognition: The FINGER Randomized Controlled Trial. J Alzheimers Dis. 2017;59(4):1459-1470.
352. Tucker LA. Physical activity and telomere length in U.S. men and women: An NHANES investigation. Prev Med.
2017;100:145-151.
353. Huang HC, Wong MK, Yang YH, Chiu HY, Teng CI. Impact of Playing Exergames on Mood States: A Randomized
Controlled Trial. Cyberpsychol Behav Soc Netw. 2017;20(4):246-250.
354. O'connell S, Ólaighin G, Kelly L, et al. These Shoes Are Made for Walking: Sensitivity Performance Evaluation of
Commercial Activity Monitors under the Expected Conditions and Circumstances Required to Achieve the
International Daily Step Goal of 10,000 Steps. PLoS ONE. 2016;11(5):e0154956.
355. Ferreira CF, Bernardi JR, Bosa VL, et al. Correlation between n-3 polyunsaturated fatty acids consumption and
BDNF peripheral levels in adolescents. Lipids Health Dis. 2014;13:44.
356. Witte AV, Kerti L, Hermannstädter HM, et al. Long-chain omega-3 fatty acids improve brain function and
structure in older adults. Cereb Cortex. 2014;24(11):3059-68.
357. Saber H, Yakoob MY, Shi P, et al. Omega-3 Fatty Acids and Incident Ischemic Stroke and Its Atherothrombotic and
Cardioembolic Subtypes in 3 US Cohorts. Stroke. 2017;48(10):2678-2685.
358. Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF. Supplementation with n3 fatty acid ethyl esters increases
large and small artery elasticity in obese adults on a weight loss diet. J Nutr. 2013;143(4):437-41.
359. Yassine HN, Braskie MN, Mack WJ, et al. Association of Docosahexaenoic Acid Supplementation With Alzheimer
Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017;74(3):339-347.
360. Allaire J, Couture P, Leclerc M, et al. A randomized, crossover, head-to-head comparison of eicosapentaenoic
acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the
Comparing EPA to DHA (ComparED) Study. Am J Clin Nutr. 2016;104(2):280-7.
361. Vors C, Allaire J, Marin J, et al. Inflammatory gene expression in whole blood cells after EPA vs. DHA
supplementation: Results from the ComparED study. Atherosclerosis. 2017;257:116-122.
362. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar
depression. J Clin Psychiatry. 2012;73(1):81-6.
363. Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH. Meta-analysis and meta-regression of omega-
3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6:e756.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
364. Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na+ currents in HEK293t
cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc Natl Acad Sci USA.
1998;95(5):2680-5.
365. Hallaq H, Sellmayer A, Smith TW, Leaf A. Protective effect of eicosapentaenoic acid on ouabain toxicity in
neonatal rat cardiac myocytes. Proc Natl Acad Sci USA. 1990;87(20):7834-8.
366. Abd allah ES, Gomaa AM, Sayed MM. The effect of omega-3 on cognition in hypothyroid adult male rats. Acta
Physiol Hung. 2014;101(3):362-76.
367. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gómez-pinilla F. A high-fat, refined sugar diet reduces hippocampal
brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience. 2002;112(4):803-14.
368. Sun J, Wang F, Hong G, et al. Antidepressant-like effects of sodium butyrate and its possible mechanisms of
action in mice exposed to chronic unpredictable mild stress. Neurosci Lett. 2016;618:159-166.
369. Valvassori SS, Varela RB, Arent CO, et al. Sodium butyrate functions as an antidepressant and improves cognition
with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress. Curr
Neurovasc Res. 2014;11(4):359-66.
370. Zhou D, Pan Q, Xin FZ, et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by
improving gut microbiota and gastrointestinal barrier. World J Gastroenterol. 2017;23(1):60-75.
371. Costa J, Lunet N, Santos C, Santos J, Vaz-carneiro A. Caffeine exposure and the risk of Parkinson's disease: a
systematic review and meta-analysis of observational studies. J Alzheimers Dis. 2010;20 Suppl 1:S221-38.
372. Kumar PM, Paing SS, Li H, et al. Differential effect of caffeine intake in subjects with genetic susceptibility to
Parkinson's Disease. Sci Rep. 2015;5:15492.
373. Khadrawy YA, Salem AM, El-shamy KA, Ahmed EK, Fadl NN, Hosny EN. Neuroprotective and Therapeutic Effect of
Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone. J Diet Suppl. 2017;14(5):553-572.
374. Wang P, Heber D, Henning SM. Quercetin increased bioavailability and decreased methylation of green tea
polyphenols in vitro and in vivo. Food Funct. 2012;3(6):635-42.
375. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-
methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos. 2003;31(5):572-9.
376. Kuriyama S, Hozawa A, Ohmori K, et al. Green tea consumption and cognitive function: a cross-sectional study
from the Tsurugaya Project 1. Am J Clin Nutr. 2006;83(2):355-61.
377. Root M, Ravine E, Harper A. Flavonol Intake and Cognitive Decline in Middle-Aged Adults. J Med Food.
2015;18(12):1327-32.
378. Scholey A, Downey LA, Ciorciari J, et al. Acute neurocognitive effects of epigallocatechin gallate (EGCG). Appetite.
2012;58(2):767-70.
379. Back SE, Mccauley JL, Korte KJ, et al. A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in
Veterans With Posttraumatic Stress Disorder and Substance Use Disorders. J Clin Psychiatry. 2016
380. Caruana M, Vassallo N. Tea Polyphenols in Parkinson's Disease. Adv Exp Med Biol. 2015;863:117-37.
381. Li FJ, Ji HF, Shen L. A meta-analysis of tea drinking and risk of Parkinson's disease. ScientificWorldJournal.
2012;2012:923464.
382. Froeliger B, Mcconnell PA, Stankeviciute N, Mcclure EA, Kalivas PW, Gray KM. The effects of N-Acetylcysteine on
frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-
blind, placebo-controlled fMRI pilot study. Drug Alcohol Depend. 2015;156:234-42.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
383. Prado E, Maes M, Piccoli LG, et al. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study.
Redox Rep. 2015;20(5):215-22.
384. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, Van den brink W. Efficacy of N-acetylcysteine in the
treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res.
2011;17(4):211-6.
385. Singh B, Parsaik AK, Mielke MM, et al. Association of mediterranean diet with mild cognitive impairment and
Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;39(2):271-82.
386. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive
impairment. Arch Neurol. 2009;66(2):216-25.
387. Farràs M, Valls RM, Fernández-castillejo S, et al. Olive oil polyphenols enhance the expression of cholesterol
efflux related genes in vivo in humans. A randomized controlled trial. J Nutr Biochem. 2013;24(7):1334-9.
388. Daccache A, Lion C, Sibille N, et al. Oleuropein and derivatives from olives as Tau aggregation inhibitors.
Neurochem Int. 2011;58(6):700-7.
389. De luis DA, Izaola O, Primo D, et al. Biochemical, Anthropometric and Lifestyle Factors Related with Weight
Maintenance after Weight Loss Secondary to a Hypocaloric Mediterranean Diet. Ann Nutr Metab. 2017;71(3-
4):217-223.
390. Assaf-balut C, García de la torre N, Durán A, et al. A Mediterranean diet with additional extra virgin olive oil and
pistachios reduces the incidence of gestational diabetes mellitus (GDM): A randomized controlled trial: The St.
Carlos GDM prevention study. PLoS ONE. 2017;12(10):e0185873.
391. Eguaras S, Bes-rastrollo M, Ruiz-canela M, Carlos S, De la rosa P, Martínez-gonzález MA. May the Mediterranean
diet attenuate the risk of type 2 diabetes associated with obesity: the Seguimiento Universidad de Navarra (SUN)
cohort. Br J Nutr. 2017;117(10):1478-1485.
392. Hernáez Á, Remaley AT, Farràs M, et al. Olive Oil Polyphenols Decrease LDL Concentrations and LDL
Atherogenicity in Men in a Randomized Controlled Trial. J Nutr. 2015;145(8):1692-7.
393. Santangelo C, Filesi C, Varì R, et al. Consumption of extra-virgin olive oil rich in phenolic compounds improves
metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of
circulating visfatin. J Endocrinol Invest. 2016;39(11):1295-1301.
394. Liu X, Kris-etherton PM, West SG, et al. Effects of canola and high-oleic-acid canola oils on abdominal fat mass in
individuals with central obesity. Obesity (Silver Spring). 2016;24(11):2261-2268.
395. Jones PJ, Senanayake VK, Pu S, et al. DHA-enriched high-oleic acid canola oil improves lipid profile and lowers
predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial. Am J Clin Nutr.
2014;100(1):88-97.
396. Rosato V, Temple NJ, La vecchia C, Castellan G, Tavani A, Guercio V. Mediterranean diet and cardiovascular
disease: a systematic review and meta-analysis of observational studies. Eur J Nutr. 2017
397. Rainey-smith SR, Brown BM, Sohrabi HR, et al. Curcumin and cognition: a randomised, placebo-controlled,
double-blind study of community-dwelling older adults. Br J Nutr. 2016;115(12):2106-13.
398. Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a
healthy older population. J Psychopharmacol (Oxford). 2015;29(5):642-51.
399. Morales I, Cerda-troncoso C, Andrade V, Maccioni RB. The Natural Product Curcumin as a Potential Coadjuvant in
Alzheimer's Treatment. J Alzheimers Dis. 2017;60(2):451-460.
400. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with
Alzheimer's disease. Curr Alzheimer Res. 2013;10(1):104-7.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
401. De sousa RT, Van de bilt MT, Diniz BS, et al. Lithium increases plasma brain-derived neurotrophic factor in
acute bipolar mania: a preliminary 4-week study. Neurosci Lett. 2011;494(1):54-6.
402. Zheng H, Jia L, Liu CC, et al. TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway. J
Neurosci. 2017;37(7):1772-1784.
403. Leussis MP, Berry-scott EM, Saito M, et al. The ANK3 bipolar disorder gene regulates psychiatric-related
behaviors that are modulated by lithium and stress. Biol Psychiatry. 2013;73(7):683-90.
404. Gottschalk MG, Leussis MP, Ruland T, Gjeluci K, Petryshen TL, Bahn S. Lithium reverses behavioral and axonal
transport-related changes associated with ANK3 bipolar disorder gene disruption. Eur Neuropsychopharmacol.
2017;27(3):274-288.
405. Mirhosseini N, Vatanparast H, Kimball SM. The Association between Serum 25(OH)D Status and Blood Pressure
in Participants of a Community-Based Program Taking Vitamin D Supplements. Nutrients. 2017;9(11)
406. Moon JH, Lim S, Han JW, et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and
dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol (Oxf). 2015;83(1):36-42.
407. Etgen T, Sander D, Bickel H, Sander K, Förstl H. Vitamin D deficiency, cognitive impairment and dementia: a
systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2012;33(5):297-305.
408. Goodwill AM, Campbell S, Simpson S, et al. Vitamin D status is associated with executive function a decade later:
Data from the Women's Healthy Ageing Project. Maturitas. 2018;107:56-62.
409. Feart C, Helmer C, Merle B, et al. Associations of lower vitamin D concentrations with cognitive decline and long-
term risk of dementia and Alzheimer's disease in older adults. Alzheimers Dement. 2017;13(11):1207-1216.
410. Bucova M, Suchankova M, Tibenska E, et al. TREM-2 Receptor Expression Increases with 25(OH)D Vitamin Serum
Levels in Patients with Pulmonary Sarcoidosis. Mediators Inflamm. 2015;2015:181986.
411. Chu F, Ohinmaa A, Klarenbach S, Wong ZW, Veugelers P. Serum 25-Hydroxyvitamin D Concentrations and
Indicators of Mental Health: An Analysis of the Canadian Health Measures Survey. Nutrients. 2017;9(10)
412. Jääskeläinen T, Knekt P, Suvisaari J, et al. Higher serum 25-hydroxyvitamin D concentrations are related to a
reduced risk of depression. Br J Nutr. 2015;113(9):1418-26.
413. Black LJ, Jacoby P, Allen KL, et al. Low vitamin D levels are associated with symptoms of depression in young
adult males. Aust N Z J Psychiatry. 2014;48(5):464-71.
414. Kassi E, Nasiri-ansari N, Spilioti E, et al. Vitamin D interferes with glucocorticoid responsiveness in human
peripheral blood mononuclear target cells. Cell Mol Life Sci. 2016;73(22):4341-4354.
415. Akin F, Ayça B, Köse N, et al. Serum vitamin D and C-reactive protein levels are independently associated with
diastolic dysfunction. J Investig Med. 2014;62(1):43-8.
416. Verdoia M, Schaffer A, Barbieri L, et al. Impact of gender difference on vitamin D status and its relationship with
the extent of coronary artery disease. Nutr Metab Cardiovasc Dis. 2015;25(5):464-70.
417. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild
to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging.
2014;9:947-61.
418. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for
6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and
safety. BMC Med. 2010;8:51.
419. O'neal-moffitt G, Delic V, Bradshaw PC, Olcese J. Prophylactic melatonin significantly reduces Alzheimer's
neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice.
Mol Neurodegener. 2015;10:27.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
420. Choi TY, Kwon JE, Durrance ES, Jo SH, Choi SY, Kim KT. Melatonin inhibits voltage-sensitive Ca(2+) channel-
mediated neurotransmitter release. Brain Res. 2014;1557:34-42
421. Feart C, Letenneur L, Helmer C, et al. Plasma Carotenoids Are Inversely Associated With Dementia Risk in an
Elderly French Cohort. J Gerontol A Biol Sci Med Sci. 2016;71(5):683-8.
422. Lakey-beitia J, Doens D, Jagadeesh kumar D, et al. Anti-amyloid aggregation activity of novel carotenoids:
implications for Alzheimer's drug discovery. Clin Interv Aging. 2017;12:815-822.
423. Bahonar A, Saadatnia M, Khorvash F, Maracy M, Khosravi A. Carotenoids as Potential Antioxidant Agents in
Stroke Prevention: A Systematic Review. Int J Prev Med. 2017;8:70.
424. Li X, Xu J. Dietary and circulating lycopene and stroke risk: a meta-analysis of prospective studies. Sci Rep.
2014;4:5031.
425. Jacques PF, Lyass A, Massaro JM, Vasan RS, D'agostino RB. Relationship of lycopene intake and consumption of
tomato products to incident CVD. Br J Nutr. 2013;110(3):545-51.
426. Yang Y, Bae M, Park YK, et al. Histone deacetylase 9 plays a role in the antifibrogenic effect of astaxanthin in
hepatic stellate cells. J Nutr Biochem. 2017;40:172-177.
427. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome
in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the
American Academy of Neurology. Neurology. 2016;87(24):2585-2593.
428. Ferri R, Fulda S, Allen RP, et al. World Association of Sleep Medicine (WASM) 2016 standards for recording and
scoring leg movements in polysomnograms developed by a joint task force from the International and the
European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). Sleep Med. 2016;26:86-95.
429. Schutte-rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of
chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
430. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical Practice Guideline for the Treatment
of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed
Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular
Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical
Practice Guideline. J Clin Sleep Med. 2015;11(10):1199-236.
431. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a
review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656-62.
432. Al-karawi D, Jubair L. Bright light therapy for nonseasonal depression: Meta-analysis of clinical trials. J Affect
Disord. 2016;198:64-71.
433. Applegate WB, Miller ST, Elam JT, et al. Nonpharmacologic intervention to reduce blood pressure in older
patients with mild hypertension. Arch Intern Med. 1992;152(6):1162-6.
434. Juraschek SP, Miller ER, Weaver CM, Appel LJ. Effects of Sodium Reduction and the DASH Diet in Relation to
Baseline Blood Pressure. J Am Coll Cardiol. 2017;70(23):2841-2848.
435. Wu J, Xun P, Tang Q, Cai W, He K. Circulating magnesium levels and incidence of coronary heart diseases,
hypertension, and type 2 diabetes mellitus: a meta-analysis of prospective cohort studies. Nutr J. 2017;16(1):60.
436. Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-
analysis of Randomized Controlled Trials. Pain Physician. 2016;19(1):E97-112.
437. Peikert A, Wilimzig C, Köhne-volland R. Prophylaxis of migraine with oral magnesium: results from a prospective,
multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257-63.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
438. Abbasi B, Kimiagar M, Sadeghniiat K, Shirazi MM, Hedayati M, Rashidkhani B. The effect of magnesium
supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. J Res Med Sci.
2012;17(12):1161-9.
439. Vicković S, Pjević M, Uvelin A, Pap D, Nikolić D, Lalić I. MAGNESIUM SULFATE AS AN ADJUVANT TO ANESTHESIA
IN PATIENTS WITH ARTERIAL HYPERTENSION. Acta Clin Croat. 2016;55(3):490-6.
440. Zhao M, Feng R, Shao D, et al. Mg(2+)-dependent facilitation and inactivation of L-type Ca(2+) channels in guinea
pig ventricular myocytes. J Pharmacol Sci. 2015;129(3):143-9.
441. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic
heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-9.
442. Shoeibi A, Olfati N, Soltani sabi M, Salehi M, Mali S, Akbari oryani M. Effectiveness of coenzyme Q10 in
prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg.
2017;117(1):103-109.
443. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive.
Cephalalgia. 2002;22(2):137-41.
444. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention.
Headache. 2003;43(1):76-8.
445. Bickel D, Röder T, Bestmann HJ, Brune K. Identification and characterization of inhibitors of peptido-leukotriene-
synthesis from Petasites hybridus. Planta Med. 1994;60(4):318-22.
446. Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective
preventive treatment for migraine. Neurology. 2004;63(12):2240-4.
447. Derosa G, D'angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in
subjects with low cardiovascular risk. Expert Opin Biol Ther. 2013;13(4):475-82.
448. Spigoni V, Aldigeri R, Antonini M, et al. Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice
and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized,
Double Blind, Placebo-Controlled Study. Int J Mol Sci. 2017;18(7)
449. Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid
pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on
stable cholesterol-lowering treatment. Lipids Health Dis. 2012;11:123.
450. Pérez-rubio KG, González-ortiz M, Martínez-abundis E, Robles-cervantes JA, Espinel-bermúdez MC. Effect of
berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat
Disord. 2013;11(5):366-9.
451. Niu W, Qi Y, Qian Y, Gao P, Zhu D. The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4
polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls.
Hypertens Res. 2009;32(12):1060-6.
452. Xu M, Zhao J, Zhang Y, et al. Apolipoprotein E Gene Variants and Risk of Coronary Heart Disease: A Meta-
Analysis. Biomed Res Int. 2016;2016:3912175.
453. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk
factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement.
2015;11(6):718-26.
454. Acker BW, Cash BD. Medicinal Foods for Functional GI Disorders. Curr Gastroenterol Rep. 2017;19(12):62.
455. Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Postgrad Med. 2017
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
456. Wilkins T, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am Fam Physician.
2017;96(3):170-178.
457. Vicario M, Santos A, Violant D, Nart J, Giner L. Clinical changes in periodontal subjects with the probiotic
Lactobacillus reuteri Prodentis: a preliminary randomized clinical trial. Acta Odontol Scand. 2013;71(3-4):813-9.
458. Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management
of periodontal disease: a preliminary randomized clinical trial. J Oral Microbiol. 2010;2
459. Mcloughlin RF, Berthon BS, Jensen ME, Baines KJ, Wood LG. Short-chain fatty acids, prebiotics, synbiotics, and
systemic inflammation: a systematic review and meta-analysis. Am J Clin Nutr. 2017;106(3):930-945.
460. Williams NC, Johnson MA, Shaw DE, et al. A prebiotic galactooligosaccharide mixture reduces severity of
hyperpnoea-induced bronchoconstriction and markers of airway inflammation. Br J Nutr. 2016;116(5):798-804.
461. Zahedi MJ, Behrouz V, Azimi M. Low FODMAPs diet vs. general dietary advice improves clinical response in
patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled trial. J Gastroenterol
Hepatol. 2017
462. Eswaran S, Farida JP, Green J, Miller JD, Chey WD. Nutrition in the management of gastrointestinal diseases and
disorders: the evidence for the low FODMAP diet. Curr Opin Pharmacol. 2017;37:151-157.
463. Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides
and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Nutrition.
2018;45:24-31.
464. Dimidi E, Rossi M, Whelan K. Irritable bowel syndrome and diet: where are we in 2018?. Curr Opin Clin Nutr
Metab Care. 2017;20(6):456-463.
465. Esposito G, Capoccia E, Turco F, et al. Palmitoylethanolamide improves colon inflammation through an enteric
glia/toll like receptor 4-dependent PPAR-α activation. Gut. 2014;63(8):1300-12.
466. Bergen AW, Javitz HS, Krasnow R, et al. Nicotinic acetylcholine receptor variation and response to smoking
cessation therapies. Pharmacogenet Genomics. 2013;23(2):94-103.
467. Chen LS, Baker TB, Jorenby D, et al. Genetic variation (CHRNA5), medication (combination nicotine replacement
therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278-82.
468. Koopmann A, Bez J, Lemenager T, et al. The Effect of Nicotine on HPA Axis Activity in Females is Modulated by
the FKBP5 Genotype. Ann Hum Genet. 2016;80(3):154-61.
469. Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the physiological markers of stress:
Systematic review and meta-analysis. J Psychiatr Res. 2017;95:156-178.
470. Hoge EA, Bui E, Palitz SA, et al. The effect of mindfulness meditation training on biological acute stress responses
in generalized anxiety disorder. Psychiatry Res. 2017
471. Twal WO, Wahlquist AE, Balasubramanian S. Yogic breathing when compared to attention control reduces the
levels of pro-inflammatory biomarkers in saliva: a pilot randomized controlled trial. BMC Complement Altern
Med. 2016;16:294.
472. Levine GN, Lange RA, Bairey-merz CN, et al. Meditation and Cardiovascular Risk Reduction: A Scientific Statement
From the American Heart Association. J Am Heart Assoc. 2017;6(10)
473. Gruzelier JH. EEG-neurofeedback for optimising performance. I: a review of cognitive and affective outcome in
healthy participants. Neurosci Biobehav Rev. 2014;44:124-41.
474. Van der kolk BA, Hodgdon H, Gapen M, et al. A Randomized Controlled Study of Neurofeedback for Chronic
PTSD. PLoS ONE. 2016;11(12):e0166752.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
475. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of
safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and
anxiety in adults. Indian J Psychol Med. 2012;34(3):255-62.
476. Zhu MY, Wang WP, Huang J, Regunathan S. Chronic treatment with glucocorticoids alters rat hippocampal and
prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. J
Neurochem. 2007;103(5):1811-20.
477. Nabi H, Bochud M, Glaus J, et al. Association of serum homocysteine with major depressive disorder: results
from a large population-based study. Psychoneuroendocrinology. 2013;38(10):2309-18.
478. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and
monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228-32.
479. Sachdev PS, Parslow RA, Lux O, et al. Relationship of homocysteine, folic acid and vitamin B12 with depression in
a middle-aged community sample. Psychol Med. 2005;35(4):529-38.
480. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative
disorders. Trends Neurosci. 2003;26(3):137-46.
481. Troen AM. The central nervous system in animal models of hyperhomocysteinemia. Prog Neuropsychopharmacol
Biol Psychiatry. 2005;29(7):1140-51.
482. Mech AW, Farah A. Correlation of clinical response with homocysteine reduction during therapy with reduced B
vitamins in patients with MDD who are positive for MTHFR C677T or A1298C polymorphism: a randomized,
double-blind, placebo-controlled study. J Clin Psychiatry. 2016;77(5):668-71.
483. Scantamburlo G, Hansenne M, Geenen V, Legros JJ, Ansseau M. Additional intranasal oxytocin to escitalopram
improves depressive symptoms in resistant depression: an open trial. Eur Psychiatry. 2015;30(1):65-8.
484. Van cappellen P, Way BM, Isgett SF, Fredrickson BL. Effects of oxytocin administration on spirituality and
emotional responses to meditation. Soc Cogn Affect Neurosci. 2016;11(10):1579-87.
485. Nawijn L, Van zuiden M, Koch SB, Frijling JL, Veltman DJ, Olff M. Intranasal oxytocin increases neural responses to
social reward in post-traumatic stress disorder. Soc Cogn Affect Neurosci. 2017;12(2):212-223.
486. Chen FS, Kumsta R, Von dawans B, Monakhov M, Ebstein RP, Heinrichs M. Common oxytocin receptor gene
(OXTR) polymorphism and social support interact to reduce stress in humans. Proc Natl Acad Sci USA.
2011;108(50):19937-42.
487. Mcquaid RJ, Mcinnis OA, Matheson K, Anisman H. Distress of ostracism: oxytocin receptor gene polymorphism
confers sensitivity to social exclusion. Soc Cogn Affect Neurosci. 2015;10(8):1153-9.
488. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment
and dementia in older women. JAMA. 2011;306(6):613-9.
489. Chang WP, Liu ME, Chang WC, et al. Sleep apnea and the risk of dementia: a population-based 5-year follow-up
study in Taiwan. PLoS ONE. 2013;8(10):e78655.
490. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev
Neurol. 2014;10(2):115-9.
491. Osorio RS, Gumb T, Pirraglia E, et al. Sleep-disordered breathing advances cognitive decline in the elderly.
Neurology. 2015;84(19):1964-71.
492. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk
factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement.
2015;11(6):718-26.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
493. Estruch R, Martínez-gonzález MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk
factors: a randomized trial. Ann Intern Med. 2006;145(1):1-11.
494. Chu P, Gotink RA, Yeh GY, Goldie SJ, Hunink MG. The effectiveness of yoga in modifying risk factors for
cardiovascular disease and metabolic syndrome: A systematic review and meta-analysis of randomized
controlled trials. Eur J Prev Cardiol. 2016;23(3):291-307.
495. Lin X, Zhang X, Guo J, et al. Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of
Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart
Assoc. 2015;4(7)
496. Mozaffarian D, Appel LJ, Van horn L. Components of a cardioprotective diet: new insights. Circulation.
2011;123(24):2870-91.
497. Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. Eur Rev
Med Pharmacol Sci. 2013;17(3):323-33.
498. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-
analysis. Intern Med. 2015;54(3):243-9.
499. Seo M, Heo J, Yoon J, et al. Methanobrevibacter attenuation via probiotic intervention reduces flatulence in
adult human: A non-randomised paired-design clinical trial of efficacy. PLoS ONE. 2017;12(9):e0184547.
500. Putignani L, Del chierico F, Vernocchi P, et al. Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and
IBS Along the Childhood-Adulthood Transition. Inflamm Bowel Dis. 2016;22(2):487-504.
501. Kuramoto AM. Therapeutic benefits of Tai Chi exercise: research review. WMJ. 2006;105(7):42-6.
502. Singh M. Mood, food, and obesity. Front Psychol. 2014;5:925.
503. Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. Nat Rev Neurosci. 2015;16(4):213-
25.
504. Walker FR, Pfingst K, Carnevali L, Sgoifo A, Nalivaiko E. In the search for integrative biomarker of resilience to
psychological stress. Neurosci Biobehav Rev. 2017;74(Pt B):310-320.
505. Pascoe MC, Thompson DR, Ski CF. Yoga, mindfulness-based stress reduction and stress-related physiological
measures: A meta-analysis. Psychoneuroendocrinology. 2017;86:152-168.
506. Carlson CR, Hoyle RH. Efficacy of abbreviated progressive muscle relaxation training: a quantitative review of
behavioral medicine research. J Consult Clin Psychol. 1993;61(6):1059-67.
507. Alsubaie M, Abbott R, Dunn B, et al. Mechanisms of action in mindfulness-based cognitive therapy (MBCT) and
mindfulness-based stress reduction (MBSR) in people with physical and/or psychological conditions: A systematic
review. Clin Psychol Rev. 2017;55:74-91.
508. Sears B, Bell S. The zone diet: an anti-inflammatory, low glycemic-load diet. Metab Syndr Relat Disord.
2004;2(1):24-38.
509. Montonen J, Boeing H, Fritsche A, et al. Consumption of red meat and whole-grain bread in relation to
biomarkers of obesity, inflammation, glucose metabolism and oxidative stress. Eur J Nutr. 2013;52(1):337-45.
510. Corella D, Carrasco P, Sorlí JV, et al. Mediterranean diet reduces the adverse effect of the TCF7L2-rs7903146
polymorphism on cardiovascular risk factors and stroke incidence: a randomized controlled trial in a high-
cardiovascular-risk population. Diabetes Care. 2013;36(11):3803-11.
511. Estruch R, Ros E, Martínez-gonzález MA. Mediterranean diet for primary prevention of cardiovascular disease. N
Engl J Med. 2013;369(7):676-7.
Genomind, Inc. | 2200 Renaissance Blvd. | Suite 100 | King of Prussia, PA 19406 | 877.895.8658 | www.genomind.com
MIN-RS-003-V2-042018
512. Buyken AE, Goletzke J, Joslowski G, et al. Association between carbohydrate quality and inflammatory
markers: systematic review of observational and interventional studies. Am J Clin Nutr. 2014;99(4):813-33.
513. Martucci M, Ostan R, Biondi F, et al. Mediterranean diet and inflammaging within the hormesis paradigm. Nutr
Rev. 2017;75(6):442-455.
514. Roager HM, Vogt JK, Kristensen M, et al. Whole grain-rich diet reduces body weight and systemic low-grade
inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial. Gut. 2017;
515. Gopinath B, Buyken AE, Flood VM, Empson M, Rochtchina E, Mitchell P. Consumption of polyunsaturated fatty
acids, fish, and nuts and risk of inflammatory disease mortality. Am J Clin Nutr. 2011;93(5):1073-9.
516. Hindmarch I, Rigney U, Stanley N, Quinlan P, Rycroft J, Lane J. A naturalistic investigation of the effects of day-
long consumption of tea, coffee and water on alertness, sleep onset and sleep quality. Psychopharmacology
(Berl). 2000;149(3):203-16.
517. Bonnet MH, Arand DL. Caffeine use as a model of acute and chronic insomnia. Sleep. 1992;15(6):526-36.
518. Husain AM, Yancy WS, Carwile ST, Miller PP, Westman EC. Diet therapy for narcolepsy. Neurology.
2004;62(12):2300-2.
519. Yang PY, Ho KH, Chen HC, Chien MY. Exercise training improves sleep quality in middle-aged and older adults
with sleep problems: a systematic review. J Physiother. 2012;58(3):157-63.
520. Urponen H, Vuori I, Hasan J, Partinen M. Self-evaluations of factors promoting and disturbing sleep: an
epidemiological survey in Finland. Soc Sci Med. 1988;26(4):443-50.
521. Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use. Subst Abus. 2005;26(1):1-13.
Top Related